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ABSTRACT 
Glucagon-like peptide-1 (GLP-1) is an insulinotropic hormone that 
increases insulin secretion in a glucose-dependent manner. Insulin secretion is 
only increased when concentrations of glucose is high and not at low to normal 
concentrations of glucose, therefore avoiding hypoglycemic episodes. In spite of 
its many remarkable advantages as a therapeutic agent for diabetes, GLP-1 is 
not immediately clinically applicable because of its extremely short half-life. The 
purpose of this research was to design an effective way of GLP-1 delivery for 
therapeutic use of GLP-1. The first half of the research studied the effects of 
GLP-1 delivery using a thermosensitive biodegradable triblock copolymer. The 
second half of this research was to design a new and effective GLP-1 delivery 
system for therapeutic use for type 2 diabetes treatment based upon construction 
of GLP-1 plasmid and its delivery. 
The effect of GLP-1 delivery system using biodegradable injectable 
polymer was studied. The results from the in vitro release experiment did show 
steady amount of GLP-1 released from PLGA-PEG-PLGA triblock copolymer 
formulation with zinc-complexed GLP-1 depot more than ten days after loading. 
As a result from the animal experiment with the type 2 diabetic model, it was 
evident that the GLP-1 released from the thermosensitive biodegradable 
hydrogel formulation was bioactive as it stimulated insulin secretion in vivo. 
Therefore, it was concluded that it is feasible to use PLGA-PEG-PLGA triblock 
copolymer formulation with zinc-complexed GLP-1 as a 2 week delivery system, 
making it a twice-a-month injection depot. 
For less frequent and more convenient administration of GLP-1, the GLP-
1 gene delivery system was attempted in this study. Since no reactive 
hypoglycemia occurs even with higher concentrations of GLP-1, a potent 
promoter/enhancer was used in this system. It has been established that GLP-1 
gene delivery significantly decreased blood glucose levels in a type 2 diabetic 
animal model. The results showed that delivered GLP-1 gene stimulated insulin 
secretion, indicating that GLP-1 gene delivery also represents a promising 
candidate for treatment of type 2 diabetes. 
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CHAPTER 1 
INTRODUCTION 
1.1 Overview of Diabetes Mellitus 
1.1.1 The Impact of Diabetes in United States 
There are 18.2 million people (6.3 % of the population) in the United 
States who have diabetes. Each day, approximately 2,200 people are diagnosed 
with diabetes [1]. Each year, 1.3 million people aged 20 years or older are 
diagnosed with diabetes [2]. Diabetes was the sixth leading cause of death listed 
on U.S. death certificates in 2000. This is based on the 69,301 death certificates 
in which diabetes was listed as the underlying cause of death [2]. Many people 
first become aware that they have diabetes when they develop one of its life-
threatening complications, such as kidney disease, nerve disease, need for 
amputations, heart disease, stroke, or blindness [3]. Overall, the risk for death 
among diabetic patients is about two times that of people without diabetes [2]. 
Diabetes is one of the most costly health problems in America. The total 
annual economic cost of diabetes in 2000 was estimated to be $132 billion [2]. 
The direct costs associated with diabetes represent 5.8% of the total personal 
health-care expenditures in the United States; however, diagnosed diabetes 
patients account for only 3.8% of the total United States population [4]. 
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1.1.2 Classification of Diabetes 
Diabetes is a generalized term describing a disease that can be divided 
into different types. The two main types of diabetes are type 1 diabetes and type 
2 diabetes. Type 1 diabetes is formerly called insulin-dependent or juvenile onset 
diabetes. Type 1 diabetes accounts for 5-10% of all cases of diabetes in the 
United States [2]. In a person with type 1 diabetes, the pancreatic beta cells are 
destroyed by autoimmune processes, so no insulin is produced in the pancreas 
[5]. Therefore, people with type 1 diabetes must take insulin for survival. Type 1 
diabetes is associated with autoimmune, genetic, and environmental factors [2]. 
Type 2 diabetes is formerly called non-insulin-dependent or adult-onset diabetes. 
It arises because of insulin resistance, in which the body can not use insulin 
properly, combined with relative insulin deficiency. It typically presents in rniddle 
and late life, although an increasing number of children and teenagers around 
the world are developing it due to increase in obesity. Type 2 diabetes does not 
exhibit a clear set of symptoms. When it is fully developed, there will be 
abnormalities in both insulin secretion and insulin action. It is characterized by an 
increase in basal glucose concentrations, upon which are superimposed 
exaggerated postprandial glucose excursions, induced by a combination of ~-cell 
dysfunction and impaired insulin sensitivity. Type 2 diabetes mellitus occurs 
when the pancreatic beta cell fails to generate an adequate insulin level to 
maintain euglycemia in the setting of insulin resistance. The molecular basis of 
both insulin resistance and of beta cell failure in type 2 diabetes remains unclear. 
Type 2 diabetes constitutes 90 95 % of all cases of diabetes [2], and the 
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incidence of type 2 diabetes is rising rapidly worldwide [6]. Risk factors for type 2 
diabetes include family history of diabetes, obesity, older age, physical inactivity, 
prior history of gestational diabetes, impaired glucose tolerance, and ethnicity. 
Asian Americans, Latino Americans, Native Americans, and some Pacific 
Islanders are known to have particularly high risk for type 2 diabetes [2]. 
Gestational diabetes is diagnosed in some women during pregnancy. It is 
a form of glucose intolerance, and more frequently occurs among obese women 
and women with a family history of diabetes. Some studies have shown that 20 
to 500/0 of women with a history of gestational diabetes develop diabetes in the 
next 5-1 0 years [2]. 
Other types of diabetes may account for up to 50/0 of all cases of diabetes. 
The causes of other specific types of diabetes include genetic conditions, surgery, 
drugs, infections, malnutrition, and other illnesses. 
1.1.3 Complications of Diabetes 
Diabetes is a group of clinical disorders characterized by the elevated 
level of blood glucose. Hyperglycemia plays an important role in the 
pathogenesis of all major complications associated with diabetes such as 
nephropathy [7], retinopathy [8], neuropathy [9], macrovascular disease [10], 
impaired cellular immunity [11], and abnormalities in cell growth [12] and 
differentiation [13]. 
Heart disease is the leading cause of diabetes-related deaths. The risk 
for heart disease and stroke is two to four times higher among people with 
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diabetes. More than 70% of adults with diabetes have high blood pressure which 
is defined as greater than 130/80 millimeters of mercury [2]. According to the 
American Diabetes Association, diabetes-related complications include heart 
disease, blindness, kidney disease, nervous system disease, dental disease, and 
amputations. Diabetes is the leading cause of blindness and treated end-stage 
renal disease. Each year, diabetic retinopathy causes from 12,000 to 24,000 new 
cases of blindness. A total of 41 ,046 people with diabetes began treatment for 
end-stage renal disease in 2000. About 60% to 70% of people with diabetes 
have nervous system damage, and more than 60% of nontraumatic lower limb-
amputations in United States occur among people with diabetes. Almost one-
third of people with diabetes have severe periodontal disease. People with 
diabetes are more susceptible to other illnesses. Furthermore, uncontrolled 
diabetes often leads to diabetic ketoacidosis and non ketotic coma [2]. 
1.1.4 Current Treatments 
Although there is no known cure for diabetes, researchers have found new 
and improved ways of treating diabetes. In most patients with this disease, the 
treatment goal should be to achieve blood glucose levels as near normal as 
possible. In order to survive, the type 1 diabetic patient must have insulin. Many 
people with diabetes also need to control their blood pressure and cholesterol by 
taking nledications. 
In individuals with either type 1 or type 2 diabetes, diet and exercise are 
essential management. However, it is not easy to achieve and maintain the 
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desired glucose control. Therefore, oral agents are needed for attaining the goal 
of near-normal glycemia. At present, treatment for type 2 diabetes relies on 
several approaches nlainly to reduce the hyperglycemia itself [14]. The oldest 
class of oral antihyperglycemic agents is sulfonylureas. As recently as 1994, 
sulfonylurea was the only available oral agent for the treatment of type 2 diabetes. 
It remains the most cornmonly used initial pharmacologic treatment for this 
disease because it is potent, effective, and inexpensive. Sulfonylureas work by 
binding to receptors on the surface of pancreatic islet beta-cells and stimulating 
the release of endogenous insulin [15]. However, sulfonylurea stimulation of 
insulin secretion is not glucose dependent, and hence hypoglycemia is an 
adverse effect of the treatment. Another problem with sulfonylurea is that after 
extensive treatment, many patients have shown secondary failure and no longer 
respond to sulfonylurea treatment [16]. There are several other therapies 
currently used as therapy for type 2 diabetes: biguanides, which reduce hepatic 
glucose production; thiazolidinediones, which enhance insulin action; and a-
glucosidase inhibitors, which interfere with gut glucose adsorption. 
Metformin is a biguanide, which was introduced in the United States in 
1995 [17]. In contrast to sulfonylureas, metformin does not stimulate insulin 
secretion [18]. Adverse effects of metformin include gastrOintestinal distress in up 
to 50% of patients [17]. The glucose lowering effect of metformin is generally 
equivalent when compared with sulfonylurea [19]. The a-glucosidase inhibitors 
were released in 1996. By inhibition of a-glucosidase, these inhibitors delay 
intestinal carbohydrate absorption and lower postprandial glucose excursions 
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[20]. The efficacy of a-glucosidase inhibitors is considerably less than that of 
either sulfonylurea or metformin [21]. Adverse effects of a-glucosidase inhibitors 
include flatulence, abdominal discomfort, and diarrhea. Currently, 
thiazolidinediones are represented by rosiglitazone and pioglitazone. The most 
prominent effect of thiazolidinediones is increased insulin-stimulated glucose 
uptake by skeletal muscle cells [22]. Adverse effects of thiazolidinediones include 
weight gain, edema, and anemia [23]. Mechanism of action and adverse effects 
of these oral agents is summarized in Table 1.1. As reviewed here, current 
available therapies have significant side effects and have limited efFicacy [24]. 
Therefore, newer physiological approaches are desperately needed for treatment 
of type 2 diabetes. The use of hormones, other than insulin, is a relatively new 
area of clinical investigation and therapy for the treatment of diabetes. 
1.2 Glucagon-Like Peptide-1 
1.2.1 Incretin 
The use of hormones, other than insulin, is a relatively new area of clinical 
investigation and therapy for the treatment of diabetes. It is possible to prevent 
the risk of hypoglycemia by potentiating insulin secretion in a glucose-dependent 
manner. In 1930, La barre introduced the term 'incretin' to describe the activity of 
gut that might enhance the endocrine secretion of pancreas [25]. In response to 
the ingestion of food, both insulin and insulin counter-regulatory hormones are 
released into the blood stream. 
Insulin secretion is related to the serum concentration of absorbed 
nutrients, such as glucose, amino acids, and fatty acids. Insulin secretion is also 
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Table 1.1 Mechanism and adverse effects of the oral agents for type 2 diabetes. 
Class Mechanism of action I Adverse effect 
Sulfonylureas Increase in insulin secretion 
I Hypoglycemia 
Biguanides Decrease in hepatic glucose production 
Decrease in peripheral insulin resistance 
I GI disturbances, Lactic acidosis 
Thiazolidinediones Decrease in insulin resistance 
I Anemia, Hepatic toxicity 
a-glucosidase inhibitors Decrease in gut glucose adsorption 
I GI disturbances 
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influenced by incretins. The incretins are intestinal hormones that augment 
insulin secretion in the presence of elevated glucose levels [26]. In humans, two 
gastrointestinal peptide hormones are thought to be responsible for the incretin 
effect [27]. One is glucose-dependent insulinotropic polypeptide (GIP). GIP was 
originally named 'gastric inhibitory polypeptide' [28]. GIP was discovered in 1973 
on the basis of its ability to inhibit acid secretion, but its insulinotropic properties 
were discovered soon after [29]. GIP is a peptide of 42 amino acids processed 
from a precursor of 153 amino acids [30]. As the cloning of cDNAs encoding the 
preproglucagons of the anglerfish was accomplished in the early 1980s, the second 
incretin hormone was discovered [31]. Shortly after cloning the proglucagon 
cDNAs of anglerfish, the proglucagon cDNAs of human and other nlammals were 
cloned [32]. GLP-1 is synthesized in the intestinal L-cells by posttranslational 
processing of the glucagon precursor, preproglucagon, and is released into the 
circulation in response to a meal [33]. The origin of GLP-1 is depicted in Figure 
1.1. 
GI P is known to be secreted from specific endocrine cells, the so-called K 
cells, but recent studies have indicated that GIP cells are found in the entire 
small intestinal mucosa [34]. Secretion of GIP is stimulated by carbohydrates and 
by lipids. Therefore, GIP secretion is greatly increased in response to meal 
ingestion, resulting in a 10- to 20-fold increase in the plasma concentration [35]. 
Interaction of GIP with its receptor on the pancreatiC beta cells causes an 
increase of cAMP levels, which in turn increases the intracellular calcium 
concentration and enhances the exocytosis of insulin granules [36]. The incretin 
GRPP II Glucagon I D 1..-1 ___ Ma_' ,_lo_f_p_ro_'9_I;u_ca_9_o_n_fr_a_9m_' _en_t __ -.I 
Proteolytic {f)fQa3ssing D In pancreatic a cells 
Proglucagon 
Proteolytic processing In intestinal L cells 
~ ____ G_J_~ce_n_f_m ____ ~1 I GlP·1 1 D 1.-1 _G_L_P-2_" ~ 
Figure 1.1 Origin of GLP-1. Proglucagon is cleaved into glucagons-like peptides 
and other peptides in intestinal L cells. 
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function of GIP was first suggested by one study [37] and was confirmed in 
detailed clamp-studies by another study [38]. Mice with a targeted deletion of the 
GIP receptor gene become glucose intolerant [39]. Immunoneutralization 
experiments showed that intestinal extracts contain potent insulinotropic agent in 
addition to GIP [40]. Furthermore, a study in patients with resections of different 
parts of the small intestine showed that the incretin effect does not correlate to 
the secretion of GIP, and that the distal small intestine releases an additional 
incretin hormone [41,42]. It is well known that GLP-1 isoforms GLP-1(7-37) and 
GLP-1 (7 -36)amide are the bioactive insulinotropic peptides derived from 
preproglucagon [43]. GLP-1 (7-37) and GLP-1 (7-36)amide sequence as active 
forms are described in Figure 1.2. 
Studies of the secretion of GLP-1 and GIP in type 2 diabetic patients 
have shown that meal-induced GIP secretion is normal or near-normal, whereas 
GLP-1 secretion is significantly impaired [43]. Potential therapeutic use of GLP-1 
for type 2 diabetes was derived from the study demonstrating that the glucose-
lowering actions of GLP-1 are preserved in patients with type 2 diabetes. To 
compare insulinotropic actions of exogenous incretin hormones (GIP and GLP-1), 
normal and type 2 diabetic patients participated. The effect of GIP in type-2 
diabetic patients was significantly lower than in normal subjects [44], whereas 
GLP-1 retains the glucose-lowering effects in type 2 diabetic patients [45]. GLP-1 
was capable of restoring insulin responses to glucose in type 2 diabetic patients. 
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GLP 1 (7-36) amide 
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- Leu-Glu-Gly-Gln-
Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu- Val-Lys-Gly-Arg-NH2 
GLP 1 (7-37) 
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- Leu-Glu-Gly-Gln-
Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu- Vaf-Lys-Gly-Arg-Gly 
Figure 1.2 Active forms of GLP-1 are amide and glycine extended form. 
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1.2.2 Biological Effects of GLP-1 
Binding of GLP-1 to the receptor causes activation of adenylate cyclase 
resulting in the formation of cAMP [46]. It has been known that all of the actions 
of GLP-1 are secondary to the formation of cAMP. Subsequent activation of 
protein kinase A leads to altered ion-channel activity, intracellular calcium2+ 
handling and enhanced exocytosis of insulin-containing granules [47]. A certain 
level of glucose must be present for GLP-1 to have any effect on insulin secretion. 
In addition, GLP-1 potentiates strongly the insulinotropic actions of glucose itself. 
Conversely, it seems that GLP-1 is required for glucose to exert its activity. Thus, 
in experiments in single beta cells, neither glucose nor GLP-1 alone affects 
intracellular calcium levels or membrane potential, whereas together they bring 
about a strong activation [48, 49]. 
GLP-1 conveys glucose competence to the beta cells [48]. The effects of 
glucose and GLP-1 may converge at the level of the adenosine tris phosphate 
(ATP) channels of the beta cells. These channels are sensitive to the intracellular 
KATP levels and thereby to glucose metabolism of the beta cells, but may also be 
affected by protein kinase A activated by GLP-1 [50, 51]. At any rate, it is of 
potential clinical importance that sulfonylureas, which bind to and close the KA TP 
channels and thereby cause an influx of calcium, may uncouple the glucose 
dependency of GLP-1. Thus, GLP-1 administration to isolated perfused rat 
pancreases at low-glucose perfusate concentrations, which normally does not 
affect insulin secretion, resulted in dramatic stimulation of insulin secretion after 
pretreatment with sulfonylurea drugs [52]. It is has been shown that cAMP 
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generated by activation of the GLP-1 receptor may also influence the exocytotic 
process directly and this process has been estimated to account for up to 700/0 of 
the entire secretory response. ATP may also influence the exocytotic process, 
which may therefore represent another site of convergence for the glucose and 
GLP-1-mediated signals [51]. 
Apart from its insulinotropic actions, GLP-1 has a number of effects, 
which makes it extremely desirable as type 2 diabetes treatment. Firstly, GLP-1 
enhances insulin secretion only when glucose levels are high (>250 mg/dl) [53]. 
GLP-1 potentiates glucose-induced insulin secretion, but it does not have 
any effect on unstimulated insulin secretion. Therefore, it is unlikely to cause 
hypoglycemia. Secondly, it stimulates not only insulin gene transcription, but also 
all steps of insulin biosynthesis [54]. Thus, it helps to provide a continuous supply 
of insulin for secretion. 
Also, it upregulates genes for the cellular machinery involved in insulin 
secretion [55]. In addition, GLP-1 has been shown to be capable of providing 
new ~-cells in the subjects with insufficient cells [56], and proliferation of ~-cells 
[57]. Recently, it has been found that GLP-1 receptor signaling results in a 
reduction of ~-cell apoptosis [58], which will further contribute to increased f3-cell 
mass [59]. Thirdly, GLP-1 strongly inhibits glucagon secretion. Inhibition of 
glucagon secretion is also glucose dependent [60]. As a result of the studies of 
GLP-1 infusion in diabetic patients without any residual ~-cell secretory capacity, 
GLP-1 retains glucose-lowering activity due to strong inhibition of glucagon 
secretion [61]. Further effects of GLP-1 include inhibition of gastrointestinal 
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motility, especially gastric emptying [62]. The slower rate of gastric emptying is 
desirable in diabetic patients, because it reduces postprandial increase of 
glucose level. Taken together all these effects render GLP-1 very promising as a 
therapeutic agent for type 2 diabetes. The schematic of GLP-1 actions is in 
Figure 1.3. 
1.2.3 Limitation of the Effects of GLP-1 
However, there is a problem limiting the usefulness of GLP-1 in treatment. 
The major drawback for the use of GLP-1 as therapeutic agent is the extremely 
short half-life due to rapid degradation. The rapid initial degradation is due to the 
ubiquitously expressed enzyme, dipeptidyl peptidase IV (OPP-IV) [63]. It cleaves 
off the two N-terminal amino acid residues. 
The conversion of intact, biologically active GLP-1 to its metabolites 
occurs with an apparent half-life of 1-2 minutes [64]. It has been shown that more 
than half of GLP-1 released postprandially circulates as the truncated metabolite. 
After subcutaneous injection of GLP-1, concentrations peak after 30-60 minutes 
and little remains in the circulation after 1-2 hours [65]. This means that the 
majority of exogenous GLP-1 is present in the circulation as the truncated 
metabolite. 
1.2.4 Strategies for Clinical Applications of GLP-1 
It has been reported that intravenous infusions of GLP-1 completely 
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Figure 1.3 Actions of GLP-1 in pancreas, stomach and hypothalamus. 
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intravenous infusion is not suitable for routine administration, many researchers 
have tried various other types of administration and those studies have shown 
the effectiveness of GLP-1. 
In order to delay the degradation of GLP-1, the properties of the 
injectable form have been modified. Possibilities include the preparation of GLP-
1 with protamine or zinc, as has been done with insulin [67]. However, the results 
from using various methods have shown that the period before degradation is still 
too short to get therapeutic effects from GLP-1 in diabetic subjects. Therefore, 
ITlultiple injections are required for therapeutic use of GLP-1. Although many 
practical problems still remain to be solved, a therapy based on GLP-1 is one of 
the most promising recent approaches to the treatment of Type 2 diabetes. 
A number of new approaches are currently under investigation for using 
GLP-1 as therapeutic agent. Since the extremely short half-life is due to DPP-IV 
activity, DPP-IV resistant analogs have been developed as alternatives [68]. The 
enzymatic cleavage occurs at the alanine in position two; thus analogs modified 
at this position were more resistant than GLP-1 itself. Such analogs retain a 
prolonged insulinotropic activity compared with native GLP-1. An interesting 
analog is exendin-4, a peptide of 39 amino acids isolated from the venom of 
lizards, which has 530/0 sequence homology to GLP-1. Exendin-4 is a full agonist 
at the GLP-1 receptor [69] and is resistant to actions of DPP-IV. One study 
showed that once a day intraperitoneal administration for 13 weeks in diabetic 
mice almost normalized blood glucose and reduced hemoglobin to near normal 
values [70]. In another study, both blood glucose and hemoglobin levels were 
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improved and body weight was lowered following up to 42 days of exendin-4 
treatment in experimental animal models of type 2 diabetes [71]. Also, it was 
demonstrated that 8 weeks exendin-4 treatment of Zucker fatty rats substantially 
improved glycemia, hyperinsulinemia and body weight [72]. Amylin 
pharmaceuticals presented data obtained in patients with type 2 diabetes treated 
with exendin-4, two or three times daily injection for 4 weeks, in addition to the 
conventional treatment [73]. 
More recently, numerous studies of exendin-4 treatment of diabetic 
patients have been published. After once or twice daily adrrlinistration of exendin-
4, the glucose level was significantly reduced in type 2 diabetic patients [74]. Also 
with combination of sulfonylurea and metformin, the postprandial glucose was 
significantly reduced in patients with type 2 diabetes [75]. One study showed that 
a single subcutaneous injection of exendin-4 has similar effects to overnight 
administration of intravenous GLP-1 [76]. In addition, exendin-4 given to diabetic 
patients before a mixed-nutrient liquid meal significantly lowered the postprandial 
glucose excursion [76]. In that study, exendin-4 appeared to be equally effective 
in lowering blood glucose in subjects with poorly controlled diabetes as it was in 
subjects with good glycemic control. 
Another analog, NN2211 has been developed by NovoNordisk. An acyl 
chain was linked to the native GLP-peptide, so that the peptide binds to albumin. 
This analog can lower the sensitivity to DPP-IV and also delay its absorption from 
the injection site [77]. Acute or chronic administration of NN2211 reduced 
glucose and increased insulin levels, suppressed glucagon release, and delayed 
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gastric emptying in a glucose-intolerant animal model [78]. In patients with type 2 
diabetes, a single sUbcutaneous injection of NN2211 reduced glucose levels to 
near-normal levels overnight and lowered postprandial glucose excursions by 
enhancing increased insulin secretion [79]. After 1 week treatment with NN2211, 
glycemia was markedly improved and endogenous glucose release was 
significantly reduced in patients with type 2 diabetes [79]. 
DPP-IV-resistant analogs exendin-4 and NN2211 have been shown to 
have the positive effects of GLP-1 in patients with type 2 diabetes. Also, their 
duration of action was extended to enable once or twice a day administration. 
Even though the use of DPP-IV-resistant analogs of GLP-1 shows considerable 
promise, it still requires frequent injection to achieve the therapeutic effect. 
The second major strategy is to inactivate DPP-IV. The use of DPP-IV 
inhibitors was suggested as a result of extreme degradation of GLP-1 in type 2 
diabetic patients [80]. Subsequently, numerous studies have indicated that 
administration of DPP-IV inhibitors can be offered to subjects at risk of 
developing diabetes. Several orally effective inhibitors of DPP-IV have been 
shown to have antidiabetic actions in various hyperglycemic animal models. For 
example, acute administration of DPP-IV inhibitors to Zucker fatty rats increased 
the percentage of intact GLP-1 from 20 to 100% [81]. Another study showed that 
after a 3-month treatment with a DPP-IV inhibitor, there was improved glucose 
tolerance as well as enhanced insulin secretion and action [82]. DPP-IV inhibition 
was also effective in obese, glucose-intolerant monkeys [83]. Several DPP-IV 
inhibitors are in clinical trials. Recently NVP-DPP728 was administered for 4 
weeks in patients with type 2 diabetes with relatively mild hyperglycemia who 
were not treated with medications [84]. Fasting plasma glucose level was 
significantly reduced after treatment, and this treatment was well-tolerated. The 
new DPP-IV inhibitor LAF237 is similar to the previous compound. Single-dose 
efficacy studies in type 2 diabetic patients showed reduced glucose and 
glucagon level, and increased GLP-1 level [85]. After treatment for 4 weeks, 
metabolic control was significantly improved. LAF237 has reached phase 3 
clinical trial [85]. 
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Treatment with the DPP-IV inhibitor significantly reduced glucose levels 
throughout the day, and insulin levels were also reduced. It is advantageous to 
use DPP-IV inhibitors because there are no adverse effects, and it is orally 
available. However. it is unclear whether DPP-IV inhibition will have long-term 
effects. Because DPP-IV metabolizes a large number of regulatory peptides, the 
effect of inhibitors cannot be entirely attributed to GLP-1. For example, since 
GLP-2, an intestinal growth factor, is also a substrate of DPP-IV, DPP-IV 
inhibition may have an effect on intestinal proliferation [80]. 
1.3 Polymeric Drug Delivery Systems 
1.3.1 Overview of Polymeric Drug Delivery Systems 
Polymeric drug delivery is the most widely studied area of drug delivery in 
recent years. Polymeric systems in a matrix or reservoir form can offer sustained 
and controlled release of drugs. Another advantage is that polymers can be 
manipulated to possess certain properties for physiological criteria. Advantage of 
polymeric drug delivery systems may provide advantages such as increased 
efficacy and reduced side effects and toxicity [86]. 
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Drug therapy via the intravenous route of administration is the most direct 
way to achieve target concentrations in serum. However, this method has several 
disadvantages including dose limitations, toxicity, and low availability. Therefore, 
multiple injections are required for effective treatment. 
Recently, many therapeutic proteins, peptides, or DNA-based drugs have 
become available due to advances in biotechnology. These therapeutic 
macromolecules have drawn increasing attention in drug delivery. Conventional 
routes of administration of these drugs require frequent injection to achieve 
therapeutic concentration in blood, because they have very short half-lives in 
blood plasma and are susceptible to physical or chemical degradation. This 
results in poor patient compliance and possible side effects [87-89]. As a result, 
biomedical polymers are designed to solve these problems. In order to reduce 
the frequency of injection of peptide and protein drugs, numerous attempts have 
been made to develop implantable or injectable systems for sustained and 
controlled release. Polymeric systems may also protect against the harsh 
environment when delivering peptides and proteins orally. 
Also, polymeric drug delivery systems can be applied to targetable 
delivery systems including nonviral gene delivery carriers. Biodegradable 
polymers and stimuli-sensitive polymers are the keys to designing suitable 
delivery systems for bioactive agents. In the subsequent sections, aspects of 
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biodegradable polymers, thermosensitive polymers, and non-viral gene carriers 
will be discussed. 
1.3.2 Biodegradable Polymers 
Many synthetic and natural polymers have been studied for implantable 
drug delivery applications. Implantable polymers can be inserted into the body by 
a surgical procedure. Biocompatibility is required for the implantable polymer. 
Biodegradable polymers are better for implants because there is no need for 
surgical removal. Poly (lactic acid), poly (glycolic acid), poly (caprolactone), 
polyanhydrides, poly (phosphazines) and poly (orthoesters) are examples of 
implantable polymers. 
For injectable delivery systems, poly (lactide-co-glycolide) (PLGA) was 
tested in the water miscible solvent glycofurol. When it is injected subcutaneously, 
the solvent diffuses into the bloodstream and its serum level per day fits FDA 
guidelines [87]. Also, poly (ortho-ester) semisolid formulation can be used as an 
injectable system [88]. Because it can be used under mild conditions, it is 
suitable for protein delivery. Biodegradable microspheres are injectable and 
suitable for protein/peptide delivery [89, 90]. Lupron Depot® (Ieuprorelin 
acetate/PLGA; Takeda/Abbott) for male prostate cancer [91] and Nutropin 
Depot® (human growth hormone/PLGA; Genentechl Alkermes) [92] were both 
approved for human use. Most of all, gel-forming biodegradable and 
thermosensitive polymers are suited for peptide and protein delivery due to many 
favorable characteristics [93-95]. This will be discussed in the next sections. 
1.3.3 Thermosensitive Polymers 
1.3.3.1 Nonbiodegradable Thermosensitive Polymers 
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For numerous biomedical applications and drug delivery systems, various 
approaches have been made to design polymers which respond dramatically 
around a certain transition temperature in an aqueous environment [96-113]. 
Some polymers exhibit lower critical solution temperature (LCST) in water, above 
which the polymer is not soluble in water. Among those polymers, poly (N-
isopropylacrylamide) (NIPAAm) and its copolymers have been extensively 
studied because their LCSTs are between body and room temperature. Below 
the LCST, the enthalpy term contributed by the hydrogen bonding between water 
and polar groups of the polymer causes the polymer to stay dissolved. Above the 
LCST, the hydrophobic interaction, which is an entropic term, becomes a major 
factor that triggers the polymers to collapse. Also a shift in the C-H stretching 
band was observed on the nanoscale level via atomic force microscopy [96]. 
Interestingly, the LCST of poly (NIPAAm) can be controlled via 
copolymerization with monomers having different degrees of hydrophobicity. It is 
known that higher LCST can be obtained by incorporating a hydrophilic monomer, 
while copolymerizing with a hydrophobic monomer results in lower LCST [96]. 
Another kind of thermosensitive polymer is poloxamer, poly (ethylene 
oxide)-poly (propylene oxide)-poly (ethylene oxide) (PEO-PPO-PEO), which is 
commercially available [114]. Poloxamers are a series of surfactant polymers. 
Poloxamer 407 (Pluronic F127) can form micelles at low concentrations in water. 
As the concentration increases} it can form a hydrogel at body temperature via 
packing of the micelles. Therefore, an aqueous solution of this polymer may be 
used as a parenteral drug delivery depot. However, disintegration of this depot 
happens very quickly (within 1 day) after dilution. Hence, it cannot be used for 
sustained release [114]. 
Overall these non biodegradable polymers are not suitable for parenteral 
applications due to lack of biocompatibility. 
1.3.3.2 Biodegradable Thermosensitive Polymers 
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A biodegradable and thermosensitive polymer, low molecular weight 
triblock copolymer of PLGA and poly (ethylene glycol) (PEG) was designed. It is 
a hydrophilic/hydrophobic balanced polymer [93]. After subcutaneous injection of 
this polymer in rats, the temperature-induced sol-gel transition of aqueous 
solution was observed [94]. After an intratumoral injection of an injectable 
formulation of PLGA-PEG-PLGA (ReGeI™) and paclitaxel, Oncogel™ 
(Macromed, Inc.), the water-insoluble drug was solubilized and slowly cleared 
from the injection site with minimal distribution into other organs [95]. This system 
is currently undergoing Phase II human clinical trials. This system is particularly 
suitable for sustained release of unstable peptide or protein drugs due to the 
absence of harsh processing conditions. It has been shown that sustained 
release of insulin can be achieved for 2 weeks by a single subcutaneous injection 
[115, 116]. 
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1.3.4 Peptide and Protein Release Systems 
Peptide and protein drugs have short in vivo half-lives, physical and 
chemical instability, and the low oral bioavailability. Thus, frequent injections as 
solution have been required for peptide and protein drug delivery. One way to 
solve this problem is using an injectable biodegradable polymer depot. Injectable 
biodegradable copolymers of lactic and glycolic acids (PLGAs) as controlled-
release systems for the delivery of peptide and protein drugs and vaccine 
antigens have been studied extensively [87-89]. 
1.3.4.1 Biodegradable Microspheres 
As explained earlier, frequent injections have been required for peptide 
and protein drugs because of their physical and chemical characteristics. It has 
been more than 20 years since the report of a sustained release of a 
microencapsulated protein. However, it cannot be used clinically because of the 
instability of the protein drug. In recent years, several therapeutic proteins have 
been developed due to advances in stabilization. For example, human growth 
hormone was formulated for clinical testing for monthly administration [88]. Still, 
there are problems to overcome for using protein-loaded microspheres, which 
include a "burst effect" and incomplete protein release [89]. 
1.3.4.2 Iniectable Depot Systems Via Sol-gel Transition 
Most of injectable microspheres or implant systems require complicated 
fabrication processes using organic solvents for biodegradable polymers for 
peptide and protein drug delivery. The use of organic solvents can cause 
denaturation when protein drugs are to be encapsulated [89]. In addition, the 
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solid form requires surgical insertion, which can cause tissue damage or irritation. 
These problems can be solved by using a thermosensitive, biodegradable 
hydrogel consisting of blocks of poly (ethylene oxide) and poly (L-Iactic acid). 
These copolymers exhibited temperature-dependent reversible gel-sol transitions. 
Bioactive therapeutics can be loaded into this hydrogel, which is aqueous at 
elevated temperature. The polymer can be injected when it is in the sol state. 
After subcutaneous injection, the temperature of injected polymer lowers to body 
temperature. Then, the copolymer with therapeutics forms a gel that can act as a 
sustained-release matrix for drugs [93]. 
Careful manipulation of block-lengths of PEG and PLGA led to the 
discovery of lower transition in the triblock copolymers of PEG and PLGA. The 
hydrophilic and hydrophobic balanced triblock copolymer, PEG-PLGA-PEG, 
exhibited sol-to-gel transition and gel-to-sol transition when temperature was 
increased [117]. Importantly, the lower transition can be used for drug delivery 
applications because the polymer is a sol at room temperature and becomes a 
gel at body temperature. 
Another type of triblock copolymer, PLGA-PEG-PLGA is also a 
biodegradable, biocompatible polymer that showed reverse thermal gelation 
properties [95, 118]. The polymer (ReGeI™, Macromed, Inc.) shows a unique 
characteristic which is a sol at room temperature and a gel at body temperature. 
This polymer forms a hydrogel above the transition temperature, and this 
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hydrogel interacts physically via hydrophobic domains. Dynamic mechanical 
analysis revealed that an increase in viscosity of approximately four orders of 
magnitude accompanies the sol-gel transition [95]. This ABA-type triblock 
copolymer was used as a drug delivery carrier for continuous release of human 
insulin [115, 116]. The release of human insulin from ReGe/™ exhibited no initial 
burst and a constant release rate in vitro due to the domain structure of the gel 
and modification of the association states of insulin by zinc. Animal studies using 
both Sprague-Dawley rats and type 2 diabetic Zucker diabetic fatty rats were 
performed to determine the in vivo release profile of insulin from ABA block 
copolymer. In both studies, ReGel™ formulation maintained insulin secretion for 
2 weeks. Therefore, only twice a month injection would be required for diabetic 
patients to maintain basal insulin levels [115]. Further discussion on gelation and 
drug release mechanisms will be provided in Chapter 2. 
1.3.5 Targetable Polymers 
For design of a targetable polymeric carrier, a water soluble polymer can 
be used with targeting moieties. Poly [N-(2-hydroxypropyl) methacrylamide] 
(HPMA) is a representative example. Doxorubicin has been conjugated to HPMA 
and studied for cancer therapy. The drug can be linked via a peptide spacer 
specifically recognizable by lysosomal enzymes due to the chemical modification 
of the side chain. Upon endocytosis, drugs are localized and released within the 
cells. By using this polymer, side effects were reduced, and efficacy was 
improved with a dramatic decrease in multidrug resistance [119]. 
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1.3.6 Nonviral Carriers for Plasmid DNA 
Recently, non viral polymeric gene carrier systems have been extensively 
studied. Positively charged polycationic polymer can form complexes with the 
negatively charged plasmid DNA via electrostatic interactions. A variety of 
targeting moieties may be attached to the polymer. For example, conjugation of 
lactose through a poly (ethyl glycol) (PEG) spacer to poly (L-Iysine) (PLL) 
showed enhanced transfection in cultured HepG2 cells [120]. 
As a nontoxic carrier, poly [aJpha-(4-aminobutyl)-L-glycolic acid] (PAGA) 
has been developed. PAGA is a polycationic polymer with hydrolytically 
degradable linkages [121]. It was used as a delivery carrier for IL-10 plasmid, for 
prevention of autoimmune insulitis in NOD mice [122]. Also, after repeated 
injections of PAGAlpmIL-12 complexes, the survival rate was significantly 
improved and tumor growth was inhibited in BALB/c mice bearing subcutaneous 
tumors [123]. Further reviews on nonviral gene delivery are placed in the 
following section 1.4. 
1.4 Nonviral Gene Delivery 
1.4.1 Gene Delivery 
It has been more than three decades since the concept of gene therapy 
was originally developed [124]. The major aim of gene delivery is restoration, 
modification or enhancement of cellular function by introducing genetic material 
into a target cell. The genetic material can be either DNA or RNA. The altered 
cellular function can result in increase or decrease of protein production. More 
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than 600 clinical trials have been started with more than 3500 patients worldwide. 
Several products are in Phase II and Phase III stages [125,126], and there 
already exists one commercial antisense product, Vitravene, a phosphorothioate 
oligodeoxynucleotide for the treatment of an inflammatory viral infection of the 
eye caused by cytomegalovirus [127]. In spite of promising preclinical data, the 
early clinical trials failed to demonstrate efficacy, mainly because of a lack of 
vectors capable of efficientJy introducing the therapeutic gene into the target cells 
of humans. 
DNA delivery approaches can be classified into viral and non-viral. Over 
the past decade, numerous approaches have been proposed and developed for 
transferring genes to various tissues with viral and nonviral carriers, but all have 
limitations. Currently, viral systems are more effective because they achieve 
higher efficiencies for delivery and expression. However, viruses present serious 
problems: they are expensive to produce, present quality control problems, 
potentially damaging to the cells they infect, and may cause potent immune 
responses that limit their use [128]. In addition, there is always a possibility of 
replication. For these reasons, it may be desirable to develop non-viral systems. 
Nonviral gene delivery vectors offer numerous advantages over viral vectors: 
they have excellent safety profiles, they can carry large amounts of DNA, and are 
less problematic in terms of quality control [129]. 
1.4.2 Nonviral Vectors for Gene Delivery 
1.4.2.1 Cationic Polymers 
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Cationic polymers have been used since the late 1980s [130] for gene 
delivery. Recently, nonviral gene delivery systems based on complexes of 
condensed DNA with cationic polymers have attracted great attention. The 
complexes of condensed DNA with cationic polymers not only can protect DNA 
from nuclease degradation but also have a small enough size to enter the cell 
through endocytosis. Cationic polymers contain high densities of primary amines, 
which are protonatable at neutral pH. The high density of positive charges allows 
the cationic polymers to form stable complexes with DNA. The cationic polymers 
self-assemble with DNA to generate condensed structures capable of entering 
the cell. 
Polyethylenimine (PEl) is a cationic polymer that has proven to be an 
effective transfection agent [131-133], and it has been widely used in non viral 
gene delivery. It has a high cationic charge density resulting fron, the 
protonatable amines on every third carbon [134]. Due to the high cationic charge 
density, it is able to efficiently condense DNA and has a high intrinsic endosomal 
activity as compared to other polycations [133]. PEl can be synthesized by the 
acid-catalyzed ring opening polymerization of aziridine as either a linear or a 
branched structure [135]. It has been shown that low molecular weight PEl is less 
cytotoxic than high molecular weight PEl [136]. PEl/DNA complexes must also 
bear a net positive charge in order to efficiently transfect cells [134, 136, 137]. 
PEl/DNA cOITlplexes form spheres or toroids with mean diameters ranging from 
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30 to 100 nm. In vivo gene transfer with PEl was reviewed by Remy et al. [138]. 
The highest transfection efficiency was observed when net charges are around 
neutrality after intracranial injection in mice [134]. Boletta et al. studied gene 
delivery to rat kidneys with three different forms of PEl [139]. Transfection 
efficiency was highest with moderately positively charged complexes. Branched 
PEl has been modified with polyethylene glycol (PEG) [140], targeting groups 
[120,141], and nuclear localization sequences [142, 143]. Kissel et al. grafted 
PEG to branched PEl (molecular weight 25,000) [140]. The degree of PEGylation 
and molecular weight of PEG affected DNA condensation and bioactivity of 
polymer/DNA complexes. 
Water soluble lipopolymer (WSLP) is branched PEl (molecular weight 
1800) conjugated to cholesterol on a primary amine. Typically 0.8-1.2 cholesterol 
molecules are conjugated per one PEl. Cholesterol increases the degree of 
transgene expression greatly [144]. Lipopolymers condense plasmid DNA by 
hydrophobic interactions as well as electrostatic interactions. In addition, the lipid 
coating on plasmid DNA increases its permeability through cell membranes [144]. 
WSLP has been studied and shown effects for the treatment of diseases 
including ischemic myocardium [145], diabetes [146], and cancer [147, 148]. 
Poly-L-Iysine (PLL) has been used for condensation of DNA under various 
salt conditions. However, PLL/DNA complexes are very unstable under 
physiological conditions. Modifications of PLL to enhance efficiency of gene 
delivery have been made in various ways. To minimize aggregation, lactose-
poly(ethylene-glycol)-grafted poly-L-Iysine (Lac-PEG-PLL) polymers were 
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synthesized [149]. Due to grafted PEG, Lac-PEG-PLL has higher solubility. For 
gene delivery into rat hepatocytes, galactosylated poly(L-lysine) (Gal-PLL) was 
synthesized [150]. By using different molecular weights of PLL and conjugation 
ratio of galactose, six different types of Gal-PLL were synthesized. Similarly, 
mannosylated poly(L-lysine) (Man-PLL) was synthesized [151]. Man-PLL was 
shown to express genes in murine macrophages from peritoneal exudates and 
macrophages in the liver and spleen. Based on stearyl-poly(L-lysine) (stearyl-
PLL) and low density lipoprotein (LDL), PLL was modified as the terplex system. 
This supramolecular gene carrier is intended to balance the hydrophobic and 
electrostatic interactions between stearyl-PLL, LDL, and DNA [152]. PLL-
arabinogalactan was also examined for gene delivery [153]. 
Another type of structure that has been examined for gene delivery is the 
dendrimer. Dendrimers can be either intact or fractured. Intact dendrimers have 
two arms from every branch point, whereas fractured dendrimers have zero, one, 
or to arms from each branch pOint [149]. Dendrimers can condense plasmids by 
electrostatic interactions of their terminal primary amines with the DNA 
phosphate groups. Gene transfer efficiency of these complexes is influenced by 
dendrimer concentration in the complexes. Polyamidoamine (PAMAM) 
dendrimers are highly branched spherical polymers whose surface charge and 
diameter are determined by the number of synthetic steps [154]. The structure of 
dendrimers is related to the core molecules. The stepwise polymerization begins 
with core molecules, either ammonia or ethylenediamine. 
Chitosan is a cationic monosaccharide that is biocompatible and 
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resorbable. Chitosan based gene delivery has shown low toxicity and little liver 
accumulation when low molecular weights are used [155]. It has also been 
shown that chitosan/DNA complexes can transfect various cell types with varying 
results [156, 157]. 
Biodegradable polymers such as poly[a-(4-aminobutyl)-L-glycolic acid] 
(PAGA) [158, 159], poly(D,L-lactic acid-co-glycolic acid) (PLGA) [160, 161], PEG-
PLGA-PEG [162], and PEG-PLL-g-His multiblock copolymers [163] have been 
used as non viral gene delivery carrier. PAGA, the biodegradable and water-
soluble polymer, condenses DNA and subsequently releases DNA upon 
hydrolysis of the polymer [160]. The complex showed higher in vitro gene 
transfection efficiency with lower cytotoxicity than poly-L-Iysine. PAGA has been 
used for interleukin-4 and interleukin-10 delivery for the treatment of diabetes 
[122, 164]. Plasmid DNA with PEG-PLGA-PEG has shown zero-order release of 
the plasmid up to 12 days [162]. A biodegradable multiblock-copolymer PEG-
PLL-g-His was synthesized and used for plasmid delivery [163]. The number of 
cells transfected with this polymer showed a 5-fold increase above the PLL 
control [163]. 
1.4.2.2 Cationic lipid 
Cationic lipid and neutral phospholipids such as DOPE [165] are used for 
gene delivery also. DNA complexes with cationic lipid enter cells by direct fusion 
with plasma membrane, and further fuse with endosomal or lysosomal 
membrane. After nuclear localization, plasmid DNA is maintained in an 
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extrachromosomal form [166]. The self-assembly process of these complexes 
requires interaction between lipid molecules and also interaction with the DNA 
[167]. The size and charge of the lipid/DNA complex can be optimized by 
changing the composition of complex; thus the efficiency of gene delivery can be 
optimized as well. However, the ability of control in lipid dispersion is generally 
limited [168]. The complexes of lipid and DNA are often poorly water soluble and 
their macroscopic characteristics are unstable over time, limiting their 
applications [169]. Cholesterol has been used for gene delivery in the form of 313 
[N-(N',N'-dimethlaminoethane)-carbamoyl] cholesterol (DC-Chol). Liposomes 
made from DC-Chol/DOPE have been used for neuron cell transfection in vitro 
[170]. 
1.4.3 Barriers to Effective Nonviral Gene Delivery 
The current nonviral gene delivery systems have shown low transfection 
efficiency [129]. Transfection efficiency is dependent on the efficiency of DNA 
delivery and the efficiency of DNA expression. Currently much effort is devoted to 
optimizing transfection efficiency of nonviral vectors. In the past decade, 
numerous papers have described the barriers to effective DNA delivery [171-174]. 
These barriers include (1) physical and biochemical degradation in the 
extracellular space, (2) the extracellular matrix and cell surface interactions, (3) 
internalization, (4) trafficking from endosomes to Iysosomes and subsequent 
degradation, (5) escape from endosomes into the cytoplasm, (6) dissociation of 
DNA from its carrier, (7) transfer into the nucleus, and (8) transcription for gene 
transfer (or hybridization for antisense inhibition). The gene delivery pathway is 
depicted in Figure 1.4. 
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There are three major barriers to DNA delivery into the cell [175]. The first 
major barrier is low uptake across the cell membrane. Cell membranes are 
negatively charged because of anionic sialic acid groups on the surface [176]. 
Negatively charged DNA molecules are condensed with cationic transfection 
reagents and form complexes. The uptake of polymer/DNA complexes can be 
achieved by the electrostatic interactions between the complexes and sialic acid 
groups. In addition, these complexes are taken up by cells through endocytosis, 
pinocytosis, or phagocytosis [177]. For effective DNA delivery, endocytosis 
chould be increased by a receptor-mediated targeting. The transferrin receptor 
was first investigated for receptor-mediated gene delivery [178]. All actively 
metabolizing cells require iron that is internalized by the cell as a transferrin-iron 
complex by means of receptor-mediated endocytosis. Another well studied ligand 
for potential use in receptor-mediated gene delivery is asialoglycoprotein [179]. 
This was the first ligand to be conjugated to polylysine and used to specifically 
target cells through a receptor. 
The second major barrier is inadequate release of DNA with limited 
stability. Due to the low pH and presence of enzymes within endosomes and 
Iysosomes, DNA can be degraded easily. One of the most common methods for 
increasing the in vitro transfection efficiency of polymer/DNA complexes is to 
treat the cells with chloroquine [180]. Chloroquine is thought to have a buffering 








Figure 1.4 Illustration of gene delivery pathway from outside of cell into nucleus. 
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of the endosomes and has been shown to enhance the transfection activity of 
polycation/DNA complexes [180]. Because of toxicity, this approach is limited to 
in vitro applications. Adenovirus particles have been used to enhance 
transfection of polymer/DNA complexes, but it is unlikely to be widely used in 
vivo because it may provoke inflammatory responses [181, 182]. Instead of using 
whole virus particles to enhance cytoplasmic delivery, fusogenic peptides have 
been used [183]. PEl has been known to possess intrinsic endosomalytic ability 
[131]. It has been suggested that this protonation in the endosome leads to 
endosomal swelling and bursting with subsequent enhancement of transfection 
activity. 
The third major barrier is lack of nuclear targeting. It has been known as 
the most limiting barrier to non viral gene delivery. An early report showed 50-
100% of mouse embryonic fibroblast thymidine kinase-negative (LMTK-) cells 
expressed kinase activity when the Herpes simp/ex virus thymidine kinase (HSV-
TK) gene was injected directly into the nucleus, compared with <0.01 % when 
plasmid was injected into the cytoplasm [184]. Translocation of macromolecules 
across the nuclear envelope occurs via pores that serve as size-exclusion 
barriers. Small molecules enter the nucleus by passive diffusion while larger 
macromolecules only enter via highly regulated active processes. Small 
oligonucleotides (DONs), 18-28 bp in size, have been shown to rapidly and 
preferentially accumulate into the nucleus after transfection [185, 186] and the 
size limit for passive diffusion of DDNs was found to be between 200 and 310 bp 
[187]. Transport of macromolecules should proceed through specialized nuclear 
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envelope spanning channels called nuclear pore complexes (NPCs) [188, 189]. 
Selective nuclear import of macromolecules larger than 40 kOa is mediated by 
nuclear localizing signals (NLSs). The nuclear localizing signal is recognized by a 
heterodimeric protein complex of importin-a and importin-J3. Importin-a then 
interacts directly with the cargo NLS, whereas importin-J3 docks the complex to 
the NPC by specifically binding to a subset of hydrophobic phenylalanine-
glycine-rich repeats [190, 191]. Therefore, larger nucleic acids and plasmids 
without nuclear targeting component cannot enter the pores passively. 
1.5 Rationale for Study 
Glucagon-like peptide-1 (GLP-1) is an insulinotropic hormone produced 
by intestinal L-cells. It has been proposed that GLP-1 can be used as a new 
treatment for type 2 diabetes mellitus because it stimulates insulin secretion and 
its effectiveness is maintained in type 2 diabetic patients. In spite of its many 
remarkable advantages as a therapeutic agent for diabetes, GLP-1 is not 
immediately clinically applicable because of its extrenlely short plasma half-life. 
Numerous approaches have been attempted to solve this problem, but these 
results have shown that the period before degradation is still too short to get 
therapeutic effects from GLP-1 in diabetic subjects. Therefore, multiple injections 
are required for therapeutic use of GLP-1. Although many practical problems still 
remain to be solved, a therapy based on the GLP-1 is one of the most promising 
recent approaches to the treatment of type 2 diabetes. 
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The main aim of this study was to design a new and effective GLP-1 
delivery system for therapeutic use for type 2 diabetes treatment. The first part of 
this study was based upon sustained release of GLP-1 using a biodegradable 
injectable polymer. Proteins or peptides delivery using polymers are currently 
available for therapeutic applications. One of the popular methods for protein or 
peptide delivery is to entrap them in biodegradable polymers to achieve 
sustained and controlled release rates. However, as a result of employing harsh 
preparation conditions as well as the organic solvent, loaded proteins or peptides 
can undergo conformational changes that lead to decreased structural integrity 
and compromised biological activity. One way to overcome these problems is to 
use polymer hydrogels formed by sol-gel transition in water. However, 
nonbiodegradable polymers exhibit moderate toxicity in vivo. In this study, a 
thermosensitive and biodegradable low-molecular weight PLGA-PEG-PLGA that 
exhibits sol-gel transition property in water was used as a depot for the delivery 
of GLP-1. 
In Chapter 3, construction of effective GLP-1 plasmid and its delivery 
were also studied for therapeutic use of GLP-1 for type 2 diabetes treatment. As 
mentioned earlier, nonviral gene delivery is more desirable than viral gene 
delivery system because nonviral gene delivery vectors have excellent safety 
profiles, and can carry large amounts of DNA. However, the efficiency of nonviral 
gene delivery system is not sufficient for therapeutic applications. Since the 
expression levels of the introduced gene depend mainly on the strength of 
transcriptional regulatory elements, GLP-1 plasmid was constructed by using 
optimal transcriptional regulatory elements. Also, GLP-1 plasmid was further 
modified to enhance nuclear import, because the most limiting barrier to non-
viral gene delivery is lack of nuclear targeting. 
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CHAPTER 2 
CONTROL OF BLOOD GLUCOSE BY NOVEL GLP-1 
DELIVERY SYSTEM USING PLGA-PEG-PLGA 
IN ZUCKER DIABETIC FATTY RATS 
2.1 Introduction 
Polymeric drug delivery has been very extensively studied in recent years 
[1]. Due to advances in biotechnology, many therapeutic protein and peptide 
drugs are available. Peptide and protein drugs have shown limited bioavailability 
due to their physico-chemical limitations. Thus, parenteral administration is the 
common delivery route of these therapeutics. The conventional route of 
adm,inistration such as intravenous injection, intravenous infusion, and 
subcutaneous injection require frequent injections to achieve therapeutic 
concentrations in blood. Frequent administration causes patient discomfort and 
inconvenience. To improve the quality of therapy, frequency of injection should 
be reduced. If drug is released in a sustained manner, frequency of dosing can 
be reduced. In addition to improving patient comfort, less frequent injections will 
smooth out the plasma concentration-time profiles. It will help to reduce adverse 
events and side effects. Significant effort has been made to develop irnplantable 
or injectable parenteral devices for sustained and controlled release of protein 
drugs in order to reduce the frequency of injection [1]. For example, glucagons-
like peptide-1 has a very short in vivo half-life due to rapid degradation by the 
enzyme dipetidyl peptidase-IV (OPP-IV). Continuous administration is required 
because of the short half-life. Alternative approaches are necessary for the 
clinical application of GLP-1. 
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Over the last few years, there have been increasing numbers of 
recombinant proteins available for therapeutic applications. As a result, there 
have been growing numbers of publications on delivery of therapeutic proteins or 
peptides using polymers. There has been an effort to develop injectable systems. 
Since many biomedical polymers for pharmaceutical purpose are not water-
soluble, only certain solvents may be used to dissolve the polymer when it is 
used under their toxicity limit. The concentration of the solvent in blood should be 
lower than the FDA limit per day basis [2]. One of the popular methods for protein 
or peptide delivery is to entrap those in biodegradable polymers to achieve 
sustained and controlled release rates [3]. Active drug substances will be 
released from the formulation via the combination of diffusion through the 
polymeric matrix and degradation. Most of sustained release formulations are 
designed using biodegradable polymers. The majority of biodegradable polymers 
are specifically based on the use of polyesters, such as poly-Iactides (PLAs) and 
poly (Iactide-co-glycolide) (PLGA) copolymers. The most representative example 
of biodegradable polymers used in drug delivery is poly (Iactic-co-glycolic acid). 
Once injected in the body, those polymers undergo nonenzymatic hydrolytic 
cleavage of the ester linkages to form lactic acid and glycolic acid. Lactic and 
glycolic acid are normal metabolic conlpounds which can be eliminated via the 
tri-carboxylic acid cycle as carbon dioxide and water [4]. 
As mentioned earlier, these polymers are not generally water soluble. 
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Therefore, fabrication of protein-loaded implants or microspheres using such 
polymers requires use of organic solvent. The organic solvent used in the 
formulation should be biocompatible, water miscible and easily excreted from the 
body. Loaded protein or peptide drugs may lose their biological activity. Also, it 
maybe not possible to maintain the original conformation and structural integrity 
of protein and peptide therapeutics due to harsh preparation conditions and use 
of the organic solvents. One way to overcome these problems is to use polymer 
hydrogels formed by sol-gel transition in water [5], such as Poloxamers (PEO-
PPO-PEO). However, such nonbiodegradable polymers exhibit toxicity in vivo. 
Therefore, biodegradable thermosensitive polymers which exhibit sol-gel 
transition in aqueous solution are particularly useful. The trigger of the phase 
transition occurs due to the thermoresponsive behavior of selected materials. For 
example, a low molecular weight triblock copolymer of PLGA and poly (ethylene 
glycol) (PEG) was designed, and a temperature-induced sol-gel transition of 
PEG-PLGA-PEG aqueous solution upon subcutaneous injection in rats was 
demonstrated [6, 7]. More recently, intratumoral injection of Oncogel™ 
(Macromed, Inc.), an injectable formulation of PLGA-PEG-PLGA (ReGeI™) and 
paclitaxel, demonstrated solubilization of the water-insoluble and sensitive drug 
and slow clearance of paclitaxel from the injection site with minimal distribution 
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into other organs [8]. This system is currently undergoing Phase II human clinical 
trials. In this study, a thermosensitive and biodegradable low-molecular weight 
PLGA-PEG-PLGA that exhibits sol-gel transition property in water [8] was used 
as a depot for the delivery of GLP-1 (Figure 2.1). 
Th is triblock copolymer undergoes sol-gel transition above its transition 
temperature involving an increase in viscosity by several orders of magnitude. 
The polymer exhibited sol-to-gel (lower) and gel-to-sol (upper) transitions as 
temperature monotonically increased [9]. The lower transition is important for 
drug delivery applications because the solution flows freely at room temperature 
and becomes a gel at body temperature. The lower transition may be related to 
micellar growth and intra- and intermicelle phase mixing and packing, while the 
upper transition involves breakage of micellar structure. Critical gel concentration 
(CGC) and critical gel temperature are controlled by polymer parameters, such 
as block length and composition of the triblock copolymers, and add itives, such 
as salts [9]. The hydrogel formed above the transition temperature possessed 
physical interactions between hydrophobic domains. The gel forms a controlled 
release drug depot for several weeks. One of advantages of using this polymer is 
the inherent ability to solubilize and stabilize poorly soluble and sensitive drugs, 
including proteins. The gel provided excellent control of the release of paclitaxel 
for approximately 50 days [8]. Paclitaxelloaded in the hydrophobic domain slowly 
diffuses out in the first phase of release followed by more rapid release when 
degradation of polymer matrix becomes more significant [8]. Upon subcutaneous 
injection, the in situ formed gel can maintain integrity up to several weeks. 
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Tt: Sol-Gel transition temperature (32°C) 
Figure 2.1 Illustration of injectable drug delivery system. Above the transition 
temperature, the injected polymer solution with drug forms a gel. 
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GLP-1 is a 30 amino acid peptide hormone secreted from the intestinal L-
cells in response to nutrient ingestion [10]. GLP-1 administration has been shown 
to reduce hyperglycemia with type 2 diabetic patients [11]. As reviewed in 
chapter 1, GLP-1 has a number of advantages. It makes GLP-1 a very promising 
candidate for type 2 diabetes treatment. GLP-1 is potent insulinotropic hormone, 
and its insulinotropic effect is glucose-dependent [12]. GLP-1 potentiates 
glucose-induced insulin secretion, but it does not have any effect on unstimulated 
insulin secretion. Therefore, there is no risk of hypoglycemia. It stimulates not 
only insulin gene transcription, but also all steps of insulin biosynthesis [13]. 
Therefore, insulin can be secreted continuously. GLP-1 has been shown to be 
capable of inducing new ~-cells in the subjects with insufficient number of these 
cells [14]. In addition to its effect on the ~-cells, GLP-1 strongly reduces glucagon 
secretion. Also, it inhibits gastrointestinal motility, especially gastric emptying [15]. 
The slower rate of gastric emptying reduces rapid postprandial increase of 
glucose level. All these effects render GLP-1 extremely desirable as a 
therapeutic agent for type 2 diabetes. 
In spite of numerous advantages as diabetes treatment, there is a 
problem limiting the usefulness of GLP-1. The major limitation of GLP-1 as a 
therapeutic agent is the short half-life. GLP-1 is degraded rapidly due to the 
presence of a ubiquitously expressed enzyme, DPP-IV [16]. It cleaves off the two 
N-terminal amino acid residues. The conversion of intact, biologically active GLP-
1 to its inactive metabolites occurs with an apparent half-life of 1-2 minutes [17]. 
More than half of released GLP-1 circulates as the truncated metabolite. It is 
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known that the exogenous GLP-1 is degraded by the same degradation 
mechanism [18]. Upon intravenous infusion of GLP-1, it is eliminated by kidneys 
with a half-life about 4-5 minutes [17]. After subcutaneous injection, the plasma 
half-life has been assessed to be approximately 60 minutes [19]. The simple 
subcutaneous injections of GLP-1 only lead to a small lowering of blood glucose 
and a short stimulation of insulin secretion. It has been shown that improved 
control in type 2 diabetic patients with sulfonylurea failure can be obtained by 24-
hour GLP-1 exposure [20]. 
As a consequence of poor oral bioavailability and current lack of 
alternative delivery routes, GLP-1 is presently administered parentally. The 
plasma profile after subcutaneous injection of GLP-1 has shown a sharp peak 
concentration and was lowered to an effective level in 1 to 3 hours [19, 21]. 
Therefore, continuous infusion or multiple injections are required for clinical 
application of GLP-1. When once a day administration is desired, 
pharmacological concentrations should be maintained at least 10 hours. In 
addition, it is better not to have frequent initial peak plasma concentrations as 
seen with frequent injections [22]. Therefore, the absorption rate should be 
delayed. For formulation of insulin or glucagon, zinc chloride or protamine 
sulphate has been used to protract the absorption rate [23, 24]. Complex 
formation of GLP-1 with zinc will have similar effect to complexation of insulin 
and zi nc [25]. 
In this study, a sustained release system of PLGA-PEG-PLGA polymer 
depot was used with zinc-complexed GLP-1. Zinc stabilizes GLP-1 and reduces 
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its solubility. This system was tested in Zucker diabetic fatty (ZDF) rats. ZDF rat 
is a type 2 diabetic animal model which shows impaired glucose tolerance 
caused by inherited obesity. 
2.2 In Vitro Release of GLP-1 from PLGA-PEG-PLGA 
2.2.1 Materials 
Glucagon-like peptide-1 (7-37) (GLP-1) was synthesized at the Emory 
University Microchemical Facility (Atlanta, GA). Poly((DL-lactic acid-co-glycolic 
acid)-b-ethylene glycol-b-(DL-Iactic acid-co-glycolic acid)) triblock copolymer 
(ReGeI™) was supplied by MacroMed, Inc. (Sandy, UT). Briefly, this polymer 
was synthesized from PEG1450, and lactide and glycolide in the mole ratio of 4:1 
(Figure 2.2). Under dry nitrogen atmosphere polyethylene glycol (60 g) was dried 
in a three-necked flask under vacuum (1-2 Torr) and stirring at 150°C for 3 hours. 
Lactide and glycoJide were added in the mole ratio of 4: 1, respectively, and the 
reaction mixture was heated under vacuum for 30 minutes. After all the lactide 
and glycolide were melted, 0.04 g of stannous 2-ethylhexanoate were added and 
the reaction mixture was further heated at 155°C for 8 hours. Bath temperature 
was reduced to 150°C and unreacted monomers were removed under vacuum. 
Crude polymer was dissolved in cold water (5-8°C). After complete dissolution, 
the polymer solution was heated to BO°C to effect precipitation of the polymer 
and to remove water-soluble low-molecular weight polymer and unreacted 
monomer. Precipitated polymer was isolated by decanting the supernatant and 
re-dissolving in ice-cold water. Heating, precipitation and decantation was 
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Figure 2.2 Synthesis scheme of PLGA-PEG-PLGA triblock copolymer. 
repeated once again and purified polymer was obtained. Residual water was 
removed by freeze drying to give triblock copolymer as a viscous semisolid in 
-850/0 yield. Residuallactide andglycolide monomer levels were analyzed by 
HPLC and shown much less 0.50/0 (w/w). 
2.2.2 Experimental Methods 
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The PLGA-PEG-PLGA triblock copolymer was dissolved in 30 mM 
phosphate buffer, pH 7.4 at room temperature to make a 23 % solution. For the 
first group, GLP-1 was dissolved in 1mM HCI at concentration 5 mg/mL and pH 
adjusted to 7.0 with 0.1 M NaOH. The formed suspension was incubated at 4 °C 
overnight, and mixed with PLGA-PEG-PLGA triblock copolymer solution 
prepared as described above. To select the optimal concentration of ZnGLP-1 in 
polymer solution, three different concentrations (5mg/mL, 10 mg/mL, and 20 
mg/mL) were tested. For the second group, the same amount of GLP-1 was 
precipitated in the presence of zinc prior to loading essentially as described by 
Gappa et al. [26]. After GLP-1 dissolution, zinc chloride was added (final pH was 
-3.5). Then, pH was adjusted to 7.0 with 0.1 M NaOH. The GLP-1 solution was 
mixed with PLGA-PEG-PLGA triblock copolymer solution as described above. 
Next, 1 ml of each formulation was placed in vials, incubated at 37°C until 
gels formed, and 20 ml of 10 mM PBS, pH 7.4, solution was added as release 
medium. Samples were withdrawn from the release medium and PBS was 
replaced daily. Samples were analyzed by reversed-phase high performance 
liquid chromatography (RP-HPLC) to measure the concentration of GLP-1. 
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Shimadzu SCL-10Avp liquid chromatograph was equipped with a C4 column 
(Vydac), which was previously equilibrated. The nlobile phases were water and 
acetonitrile containing 0.1 % trifluoro acetic acid (TFA) with a gradient 2% B/min 
and the flow rate was 1.2 ml/min. 
Data was analyzed by two-way ANOVA for repeated measures using a 
generalized linear model. In all cases a p value of <0.05 was considered to be 
statistically significant. 
2.2.3 Results and Discussion 
The concentration of ZnGLP-1 in polymer solution for this study was 
determined as a result of dose dependency study. The amount of released GLP-
1 was measured by reversed-phase HPLC. Figure 2.3 shows the result from the 
HPLC analysis performed on the release media. The analysis shows a sharp, 
clean peak at the retention time of 14.9 minutes, which is expected for GLP-1. 
To select the optimal concentration of ZnGLP-1 in the polymer solution for 
the in vivo study, 5, 10, and 20 mg of ZnGLP-1 was incorporated to 1 mL of 
polymer solution. Figure 2.4 shows the daily amount of released GLP-1 for each 
loading amount. When the amount of GLP-1 was increased from 5 mg to 10 mg, 
the amount of daily release was increased significantly over the period of 15 days 
and showed similar release patterns. However, when the loaded GLP-1 was 
increased from 10 mg to 20 mg, the initial release for the first day was greater in 
the case of 20 mg loading, yet the released amount after the initial release phase 
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Figure 2.4 Daily amount of released GLP-1 from PLGA-PEG-PLGA formulation in 
vitro. Released amount of GLP-1 from 20 mg GLP-1! PLGA-PEG-PLGA (open 
circle), 10 mg GLP-1! PLGA-PEG-PLGA (closed square), and 5 mg of GLP-1! 
PLGA-PEG-PLGA (open triangle) was measured for the indicated times. The 
graph represents the average ± SEM, n=3. 
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structure of the triblock copolymer hydrogel: hydrophilic domains and 
hydrophobic domains throughout the gel matrix in which the hydrophobic 
domains serve as physical crosslinks. When the drug loading is increased, the 
hydrophobic domains are saturated and the rest should remain in the hydrophilic 
domain. Drug loaded in the hydrophilic domain is responsible for initial release 
phase, which is more rapid, whereas drug loaded in the hydrophobic domain is 
responsible for slower release in the later phase. For this reason, it is possible 
that a larger amount of 20 mg of GLP-1 per gram of gel may have been subject 
to initial release compared to 10 mg loading. 
Increasing the loading from 10 mg to 20 mg of GLP-1 in the gel can 
produce the benefit of increase in released amount only for the first day which is 
not beneficial for the purpose of achieving sustained effect of GLP-1 for two 
weeks whereas increasing the loading from 5 mg to 10 mg showed more release 
over the whole duration of interest. Therefore, GLP-1 loading of 10 mg was 
chosen for further in vivo study. The in vitro release of GLP-1 from the PLGA-
PEG-PLGA polymer depot was investigated and the data are presented in Figure 
2.5. The graph shows the % cumulative amount of released GLP-1 over the 
period of 20 days. The release of GLP-1 from the triblock copolymer hydrogel 
without using zinc complex shows a big burst with more than 60 % of initial 
loading released in day 1 and 80 % released in 3 days. As compared to the first 
group, the release of zinc-complexed GLP-1 exhibited no initial burst and 
displayed constant rate and an almost linear release profile over 2 weeks to 



















Figure 2.5 Cumulative amount of released GLP-1 from PLGA-PEG-PLGA 
formulation. Released amount of GLP-1 from GLP-11 PLGA-PEG-PLGA (open 
circle) and ZnGLP-11 P LGA-PEG-PLGA (closed square) was measured for the 
indicated times. The graph represents the average ± SEM, n=3. 
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The thermosensitive, biodegradable triblock copolymer (ABA-type triblock 
copolymer composed of PLGA and PEG) in aqueous solution (ReGeI™) is a 
free-flowing sol at room temperature and becomes a gel at body temperature. 
Therefore, polymer forms a water-insoluble gel once injected. This hydrogel 
formed above transition temperature possessed physical interactions between 
hydrophobic domains (Figure 2.6). 
Dynamic mechanical analysis revealed that an increase in viscosity of 
approximately four orders of magnitude accompanies the sol-gel transition. The 
gel forms a controlled release drug depot with delivery times ranging from 1 to 6 
weeks [8]. 
The first study that den10nstrated the feasibility of using t~lis system as a 
carrier for controlled release of protein was performed with insulin [27]. No initial 
burst and a constant release of human insulin from the polymer depot in vitro 
was observed due to the domain structure of the gel and modification of the 
association states of insulin by zinc. Animal studies using Zucker diabetic fatty 
rats were performed to verify, in vivo, the release profile of insulin from this ABA 
block copolymer hydrogel. The polymer formulation maintained insulin release up 
to 2 weeks, which could allow diabetic patients to reduce the number of insulin 
injection twice a month for basal insulin requirements [28]. In this study we have 
shown that this system can also be used as a drug delivery carrier for the 
continuous release of GLP-1. The stimulating effect of zinc-complexed GLP-1 on 
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Figure 2.6 Physical crosslinks in the PLGA-PEG-PLGA in water showing 
hydrophobic domain structures. 
78 
79 
The release of zinc-complexed GLP-1 from PLGA-PEG-PLGA triblock 
copolymer showed no initial burst and constant release rate as demonstrated by 
in vitro release study. It is evident that zinc complexation provided a means to 
stabilize the peptide physically and cherrlically, and to achieve dramatic reduction 
of initial burst as compared to GLP-1 release from the same hydrogel without 
zinc. Uncomplexed GLP-1 is highly soluble in water and thus, the majority GLP-1 
stays in the hydrophilic domain of the PLGA-PEG-PLGA triblock copolymer, and 
is quickly released via water channels, exhibiting burst release in 3 days. 
2.3 In Vivo Release of GLP-1 from PLGA-PEG-PLGA 
2.3.1 Materials 
Twenty male Zucker Diabetic Fatty (ZDF) rats (410-460 g) were 
purchased from Charles River Laboratories (Wilmington, MA) at 11 weeks of age. 
All animals used in this study were housed according to the principles 
established for care and use of laboratory animals (21-23°C, 12-12 h light-dark 
cycle). They were fed ad libitum with Purina 5008 (6.5 % fat). The experimental 
protocols concerning the use of laboratory animals were reviewed and approved 
by the Institutional Animal Care and Use Committee of University of Utah. 
The ZDF is an inbred rat model through both genetic mutation and a managed 
diet. It is possible to rrlirrlic hunlan adult onset diabetes and its related 
complications, when rrlale ZDF rats are fed a diet of Purina 5008, which contains 
high fat (6.5% ). Since the ZDF rat shows impaired glucose tolerance caused by 
the inherited obesity, it is a model for type 2 diabetes [29, 30]. The obese male 
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ZDF rat is considered to be a good model for type 2 diabetes and has been used 
since the late 1980s [30]. 
2.3.2 Experimental Methods 
The experimental animals, male ZDF rats (12 weeks), were divided into 
two groups of six animals each. Both groups were fasted overnight and 
anesthesia was induced by intramuscular injection of Pentobarbital (60 mg/kg). 
The first group was injected with 1 ml of blank triblock copolymer aqueous 
solution. The second group was administrated subcutaneously 1 ml formulation 
containing 10 mg ZnGLP-1. The dose was estimated according to intravenous 
infusion data. The concentration of GLP-1 in polymer solution was selected as a 
result of a dose dependency study. At designated times (day 1, 2, 3, 4, 5, 6, 7, 9, 
11, 13, and 15), 600 ~I of blood samples were obtained from the tail vein of ZDF 
rats. 
2.3.2.1 Assay of GLP-1, Insulin, and Glucose Level 
GLP-1 concentration was determined by an ELISA kit (Linco Research) 
that measures biologically active GLP-1 forms in the sample. The samples were 
treated with dipeptidyl peptidase IV inhibitor (Linco Research). The serum insulin 
levels were determined by using insulin radioimmunoassays kit (ICN 
Pharmaceuticals, Costa Mesa, CA). The blood glucose levels of the ZDF rats were 
monitored using Accucheck-Instant (Boehringer Mannheim, Indianapolis, IN). 
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2.3.2.2 Glucose Tolerance Test 
Two groups of rats (n=3) were subjected to an intraperitoneal glucose 
tolerance test (IPGTT) at day 7. Rats were fasted for 15 hours. A basal blood 
sample was collected from a tail vein (t=O). The rats were injected with glucose 
(1.5 g I kg) intraperitoneally and additional blood samples were collected at t = 30, 
60, 120, and 180 minutes. Blood glucose levels were measured by using 
Accucheck-Instant (Boehringer Mannheim, Indianapolis, IN). 
2.3.2.3 Statistical Analysis 
The statistical program, SPSS for Windows (SPSS, Chicago, IL) was used 
for statistical analysis. Data for the effects of GLP-1 in the ZDF rats were 
analyzed by a general linear model. In all cases P values of less than 0.05 were 
taken as statistically significant. All data are presented as means ± SEM. 
2.3.3 Results and Discussion 
An animal study using ZDF rats was performed with ZnGLP-11 PLGA-
PEG-PLGA triblock copolymer formulation. The polymer solution with ZnGLP-1 
formed a gel once injected, and its integrity was maintained for about a week. 
Figure 2.7 shows the formed gel at 7th day after subcutaneous injection of 
polymer solution with ZnGLP-1. Figure 2.8 shows the plasma concentration of 
GLP-1 after subcutaneous injection as determined by ELISA. It should be noted 
that the detection is limited only to biologically active form of GLP-1. After 
injection of the formulation, GLP-1 concentration in plasma reached 200 ng/L 
Figure 2.7 The formed gel at ih day after subcutaneous injection of polymer 




300 -+- ZnGLP-1/polymer 
250 










0 5 10 15 
lime (days) 
Figure 2.8 Plasma GLP-1 levels in rats treated with ZnGLP-1/PLGA-PEG-PLGA 
formulation (closed circle) and PLGA-PEG-PLGA (open square) were assayed 
for the indicated times. The graph represents the average ± SEM, each group 
was composed of six rats. Statistical significance between groups (PLGA-PEG-
PLGA vs. ZnGLP-1/PLGA-PEG-PLGA) was determined by repeated-measures 
ANOV A: P < 0.05. 
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initially (day 1 and day 2) and later significantly higher GLP-1 levels (> 50 ng/L) 
were maintained compared to that of the control group (treated with blank 
polymer) with duration of at least 14 days. Figure 2.9 shows the insulin levels in 
the plasma samples over 15 days. Injection of blank polymer hydrogel shows the 
constant basal insulin levels of - 1.8 ug/mL. The injection of zinc-complexed 
GLP-11 PLGA-PEG-PLGA triblock copolymer induced increased insulin levels 
about 3 ug/mL initially which were maintained over several days with subsequent 
gradual decrease over 15 days. The significant difference between control and 
positive groups was found up to day 11. 
Blood glucose profile as a result of GLP-1 release is depicted in Figure 
2.10. While the injection of blank polymer resulted in no impact on the blood 
glucose level that was maintained at 350-400 mg/dL, GLP-11 PLGA-PEG-PLGA 
triblock copolymer demonstrated significant glucose lowering activity over the 15-
day period in type 2 diabetic animals. Also, the change in blood glucose level 
over time is consistent with the plasma insulin profile (Figure 2.9). 
Blood glucose profile after intraperitoneal glucose administration is shown 
in Figure 2.11. Giving 1.5 g I kg glucose evoked pronounced glucose excursions 
in both groups of animals. However, blood glucose excursion was significantly 
lower in GLP-11 PLGA-PEG-PLGA triblock copolymer treated rats following 
intraperitoneal glucose loading. At day 7, the plasn1a GLP-1 levels of GLP-11 
PLGA-PEG-PLGA triblock copolymer treated rats were maintained at higher level 
with value about 60 ng/L (compared with 20 ng/L in control animals). This figure 
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Figure 2.9 Plasma insulin levels in rats treated with ZnGLP-1/PLGA-PEG-PLGA 
formulation (closed circle) and PLGA-PEG-PLGA (open square) were assayed 
for the indicated times. The graph represents the average ± SEM, each group 
was composed of six rats. Statistical significance between groups (PLGA-PEG-
PLGA vs. ZnGLP-1/PLGA-PEG-PLGA) was determined by repeated-measures 
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Figure 2.10 Blood glucose levels in rats treated with ZnGLP-1/PLGA-PEG-PLGA 
formulation (closed circle) and PLGA-PEG-PLGA (open square) were assayed 
for the indicated times. The graph represents the average ± SEM, each group 
was composed of six rats. Statistical significance between groups (PLGA-PEG-
PLGA VS. ZnGLP-1/PLGA-PEG-PLGA) was deterrriined by repeated-measures 
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Figure 2.11 Blood glucose level in ZDF rats after glucose challenge (IPGTT). 
At day 7, blood glucose levels in rats treated with ZnGLP-1/PLGA-PEG-PLGA 
formulation (closed circle) and PLGA-PEG-PLGA (open square) were assayed 
for the indicated times after intraperitoneal glucose injection. The graph 
represents the average ± SEM, each group was composed of five rats. Statistical 
significance between groups (PLGA-PEG-PLGA vs. ZnGLP-1/PLGA-PEG-PLGA) 
was determined by repeated-measures ANOVA: P < 0.05. 
tolerance in the animals as early as 30 minutes after intraperitoneal glucose 
injection. 
Finally, subcutaneous injection of GLP-1/ PLGA-PEG-PLGA triblock 
copolymer was well tolerated, and there was no sign of chronic inflammation 
around the injection sites during the experiment. 
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The present results show that the elevated blood glucose level in type 2 
diabetic rats can be controlled by a single injection of PLGA-PEG-PLGA triblock 
copolymer formulation with zinc-complexed GLP-1 for 2 weeks. The clinical 
application of GLP-1 has been limited by its extremely short half-life of 2-3 min 
[31]. Although many practical problems still remain to be solved, a therapy based 
on the GLP-1 is one of the most promising recent approaches to the treatment of 
type 2 diabetes. A number of new approaches are currently under investigation 
for using GLP-1 as therapeutic agent [32-34]. To overcome its instability, different 
analogs of GLP-1 [33, 35] and inhibitors of dipeptidyl peptidase IV [36] are 
currently tested in clinical trials. 
Even though the use of DPP IV-resistant analogs of GLP-1 shows 
considerable promise, it still requires at least everyday injection to achieve 
therapeutic effect Moreover, a complete normalization of glucose concentrations 
has only been demonstrated with the intravenous infusion of native GLP-1 [11, 
20,31]. 
Early stage of type 2 diabetes is characterized by a progressive loss of 
first phase insulin secretion and a compensatory increased second phase 
secretion [32, 33]. Delayed insulin secretion after meal ingestion causes 
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postprandial hyperglycemia [34]. Continuous release of GLP-1 can reduce 
postprandial glycemic excursions effectively. Due to its glucose-depending 
insulinotropic effects, GLP-1 actions do not cause hypoglycemia [11]. Although 
GLP-1 is a very attractive therapeutic agent for type 2 diabetes, GLP-1 is very 
unstable in the blood stream, requiring continuous infusion or frequent 
subcutaneous injections. Thus, the use of PLGA-PEG-PLGA triblock copolymer 
as a controlled release depot for GLP-1 in type 2 diabetic patients will result in 
improved patient compliance. 
Animal studies using ZDF rats have been performed to study the 
bioactivity of the released GLP-1. The ZDF rats used were of 12 weeks of age 
with 'fully developed type 2 diabetes. Hyperglycemia initially manifested at about 
7 weeks of age, and all obese male rats fed special chow are fully diabetic by 12 
weeks [30]. As shown in Figure 2.8, the plasma GLP-1 levels were maintained in 
vivo for about two weeks at concentrations significantly higher than that of control 
group. This was manifested in increased plasma insulin and decreased blood 
glucose levels over the same time period. In Figure 2.9, insulin level reached and 
stayed at higher levels over 2 weeks as long as there was significantly increased 
GLP-1 levels in plasma. This means that the continuously released GLP-1 from 
the subcutaneously injected PLGA-PEG-PLGA triblock copolymer demonstrated 
an insulinotropic effect. Blood glucose level was accordingly maintained to the 
near normalized level as shown in Figure 2.10. The glucose level dropped to the 
level significantly lower (-200 mg/dL) than the control (-400 mg/dL) as long as 
the insulin level was maintained. In contrast, the control group in Figure 2.4 
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shows endogenous insulin levels yet this has no effect on lowering blood glucose, 
signifying insulin resistance that is characteristic of the type 2 diabetes. The 
IPGTT data suggested that released GLP-1 was able to significantly improve 
glucose tolerance. The GLP-1 treated animals had much lower peak glucose 
levels in response to the glucose challenge, with the values peaking at 390 
mg/dL (compared with 550 mg/dL in control animals); thus, the GLP-1 delivery 
system improved glucose tolerance and hyperglycemia. 
2.4 Conclusions 
As shown by the data, a steady amount of GLP-1 was released from 
PLGA-PEG-PLGA triblock copolymer formulation depot more than ten days after 
a single subcutaneous injection. It is evident that the GLP-1 released from the 
thermosensitive biodegradable hydrogel (ReGeI™) formulation is bioactive as it 
stimulates insulin secretion in vivo. Also, GLP-1 released from PLGA-PEG-PLGA 
triblock copolymer formulation depot results in the improved glucose tolerance. 
Therefore, it can be concluded that it is feasible to use PLGA-PEG-PLGA triblock 
copolymer formulation with zinc-complexed GLP-1 as a 2 week delivery system, 
making it a twice-a-month injection depot. Dose may be further adjusted by the 
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CHAPTER 3 
DESIGN OF GLUCAGON-LIKE PEPTIDE-1 PLASMID 
AND IN VITRO STUDY 
3.1 Introduction 
Glucagon-like peptide-1 (GLP-1) is a 30 amino acid hormone produced 
by intestinal L-cells. It has been proposed that GLP-1 can be used as a new 
treatment for type 2 diabetes mellitus because it acts to augment insulin 
secretion and its effectiveness is maintained in type 2 diabetic patients. In spite 
of its many remarkable advantages as a therapeutic agent for diabetes, GLP-1 is 
not immediately clinically applicable because of its extremely short half-life [1]. 
One way to overcome this drawback is GLP-1 gene delivery which enables GLP-
1 production in the body. The plasmid containing GLP-1 minigene was tested for 
in vitro transfection of mouse insulinoma cells [2]. A DNA fragment of the human 
glucagon gene encoding for GLP-1 was used for plasmid construction. GLP-1 
plasmid with GLP-1 cDNA was also tested in vivo as well as in vitro [3]. In that 
study, the expression level of GLP-1 was not high enough for normalizing blood 
glucose levels. The main aim of this study was to design an effective GLP-1 
delivery system for therapeutic use for type 2 diabetes treatment based upon 
97 
construction of an efficient GLP-1 plasmid and its delivery. 
Gene therapy can be divided into two components. One is a gene 
expression system which encodes a specific protein, and the other is a delivery 
system which controls the delivery of plasmid for gene expression. In this chapter, 
the gene expression system was studied for GLP-1 gene therapy. To make a 
gene transfer vector more efficient, expression efficiency should be enhanced. 
The expression levels of the introduced gene depend mainly on the strength of 
transcriptional regulatory elements and the transduction efficiency of the gene 
transfer vector [4]. For high-level expression, one important aspect is the 
optimization of the plasmid vector. By using optimal transcription regulatory 
elements, it will be possible to enhance expression efficiency. It is desirable to 
use strong promoters in order to obtain a high level of transcription and 
expression of the gene. Although various kinds of transcriptional regulatory 
elements have been tried, only several elements are considered ubiquitously 
strong. The examples of suitable promoters for expression of genes in animal 
cells include the beta-actin promoter, cytomegalovirus (CMV) promoter, and the 
Rous Sarcoma Virus (RSV) L TR-promoter [5]. Enhancer sequences are a set of 
eucaryotic DNA elements that increase transcriptional efficiency in a manner 
independent of their position and orientation. The physical boundaries between 
promoter and enhancer elements are not clear [4]. Most genes from higher 
eukaryotes contain introns which are removed during RNA processing. It has 
been shown that the inclusion of introns can lead to more efficient expression 
than identical constructs lacking introns [6]. Also, most eukaryotic mRNAs have a 
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poly(A) tail at their 3' ends, which is added during a complex process that 
involves cleavage of the primary transcript and a coupled polyadenylation 
reaction [4]. The poly(A) tail is important for mRNA stability and translatability [7]. 
Plasmid regulatory elements consist of promoter, enhancer, intron and 
polyadenylation signal. Since it was found that the effect of different introns and 
polyadenylation signal on expression levels is relatively small, selection of strong 
promoters/enhancers was focus of the first approach. Among many viral 
promoters/enhancers, the cytomegalovirus (CMV) promoter/enhancer has been 
found to be one of the strongest ones. Simian virus 40 (SV40) early region 
promoter/enhancer has been used as a viral promoter and has shown very high 
levels of expression in muscle, liver, and pancreas. As a cellular promoter, 
chicken ~-actin promoter showed higher expression levels than the CMV 
promoter in mouse liver [3]. 
The other approach to enhance expression efficiency is to increase 
nuclear transport of plasm ids into cells. It is known that nuclear transport of 
plasmids in mammalian cells is the main barrier in nonviral gene delivery [B]. 
After release from endosome, the therapeutic plasmid should enter the nucleus 
after which mRNA and protein can be subsequently produced. However, most 
plasmids are too large to diffuse through the nuclear pore complex (NPC) [9]. To 
enter the nucleus, exogenous gene must either contain nuclear localization 
signals (NLSs) or form oligomers with other proteins that contain an NLS [10]. 
Transcription factors are proteins known to contain NLSs. These 
transcription factors could be utilized as carrier proteins to import DNA to the 
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nucleus. Since transcription factors are known to bind to specific DNA sequences, 
if such DNA sequences are present in the cytoplasm, they can form a complex 
with these proteins. The NLSs present in this complex can then interact with the 
NLS receptor and enter the nucleus by the conventional nuclear protein import 
machinery [11]. Nuclear factor KB is a farrlily of transcription factors present in 
every cell type [12]. NFKB transcription factors are heterodimers or homodimers 
of a family of related proteins characterized by the Rei homology domain (RHO). 
They form two subfarrlilies, one with activation domains (p65, RELB, and 
c-REL) and the other without activation domain (p50, p52) [13]. The prototypical 
NFKB is a heterodimer of p65 and p50. In the absence of stimulus, most of NFKB 
is present in the cytoplasm in an inactive state in a complex with inhibitor protein 
IKB. IKB is a family of seven inhibitory subunits which can be characterized by 
multiple ankyrin-like repeats [14]. There are three IKB proteins, IKB-a, IKB-~, and 
IKB-E, that have been identified. Among these IKB proteins, IKB-a is the most 
abundant inhibitory protein for NFKB [15]. All IkBs contain multiple copies of a 30-
33 amino acid sequence, ankyrin repeats, which mediate the association 
between IKB and NFKB dimers. The ankyrin repeats interact with a conserved N-
terminal region, called the Rei homology domain of NFKB proteins. As a result of 
masking of the NLS, nuclear translocation is prevented. Signals that induce 
NFKB activity cause the phosphorylation of IKBs, their dissociation and 
subsequent degradation, allowing NFKB proteins to enter the nucleus and induce 
gene expression [12]. IKB serves as a cytoplasmic anchor for NFKB, hence when 
IKB is degraded, NFKB can migrate into the nucleus. NFKB is able to carry 
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messages into nucleus because it communicates with both the cytoplasm and 
the nucleus. However, without any stimuli to induce NFKB activity, there are 
active NFKB molecules in cytoplasm due to their low-level migration into nucleus. 
In one study, under nonstimulatory conditions, transfection was enhanced by 2.6-
to 5.8- fold by incorporating NFKB binding sites into plasmids [16]. Since nuclear 
factor KB contains a NLS, it will allow nuclear entry of plasmid by a piggyback 
mechanism. By incorporating nuclear factor KB binding sites in the constructed 
GLP-1 plasmids, it may be possible to increase the import of plasmid DNA into 
nuclei (Figure 3.1). In addition, it has been suggested that the activation of NFKB 
participates in chronic disorders including diabetes [17]. If cells are exposed to 
stressful stimuli, IKB will be rapidly phosphorylated and degraded. Thus, NFKB 
can translocate into the nucleus [18]. 
In this study, GLP-1 plasmid was designed to increase expression level 
and tested in vitro. Since gene expression level is largely regulated by the level 
of transcription, the first part of GLP-1 plasrTlid design was based on the 
optimization of transcriptional regulatory elements for higher gene expression. 
The strength of each promoter/enhancer has been tested indirectly by monitoring 
the GLP-1 gene activity following introduction into the cell via transfection of the 
plasmid/carrier complex into the cells. The second part of GLP-1 plasmid design 
was based on increasing nuclear transport which is the main barrier in non-viral 
gene delivery. By incorporating a nuclear factor KB binding site to the constructed 
GLP-1 plasm ids, the expression level can be increased due to the enhancement 





















Figure 3.1. A. Inefficient uptake of DNA into nucleus, B. Uptake of DNA is 
enhanced due to the presence of a specific DNA sequence, a NFKB binding site, 
in the plasmid. NFKB binds to the plasmid, and carry it into the nucleus due to the 
presence of a NLS in NFKB. 
plasmid with the maximal expression level was selected. For a gene delivery 
carrier, polyethylenimine (PEl) was used. 
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Although viral gene carriers can transfer gene more effectively, they have 
disadvantages, compared to nonviral gene carriers. Nonviral gene transfer 
agents have several advantages over recombinant viruses. They are 
noninfectious, less immunogenic, less cytotoxic, easy to handle, and 
reproducible. Also, they can accommodate a large DNA plasmid and be modified 
for specific cell targeting. Cationic polymers have been used as non-viral gene 
carrier. The cationic polymer forms complexes with plasmid by electrostatic 
interactions. Polymeric gene carriers can protect plasmid against enzymatic 
degradation. As reviewed in Chapter 1, PEl has been commonly used as gene 
carrier. PEl is synthesized by acid-catalyzed, ring-opening polymerization of 
aziridine. It has been widely used because its ability of complex formation with 
DNA within physiological pH range and endosomal escape [19]. PEl has shown 
relatively high transfection efficiency due to the chemical properties. When PEl 
presents in the endosome, protons are accumulated in the endosome due to the 
proton sponge effect of PEL Since every third atom in PEl is a protonarable 
nitrogen, low pH results in osmotic swelling and rupture inside the endosomal 
compartment. Polymer swells by internal charge repulsion and osmotic swelling 
of the endosome follows. Thus, the complex can escape easily from endosome 
[19]. However, it has shown high cytotoxicity in different cells. Also, PEl 
complexes with plasmid are easy to aggregate. Various approaches have been 
made to reduce the cytotoxicity and increase the solubility of PEl/plasmid 
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complex. As modified PEl gene carrier, biodegradable PEl has been developed 
with difunctional PEG succinmidyol succinate [20]. Since this copolymer is 
degraded into small PEl and PEG due to biodegradable ester linkages in the 
backbone, it improves the cytotoxicity and the solubility of complexes. Insoluble 
lipoparticulates (ISLPs) are another example of modified PEl gene carrier. A T-
shaped liponanomer was synthesized using linear PEl as a headgroup and 
cholesteryl chloroformate as a hydrophobic lipid anchor. ISLPs condensed 
plasmid efficiently and protected plasmid from degradation by nucleases [21]. 
Also, PEl has been conjugated with transferrin [22], galactose [23], folate [24], 
and NLS [25] to reduce the cytotoxic effects and aggregation. 
In this study, branced PEl (25,000 Da) was used because it has been 
widely studied and shown efficient transfection over a wide range of cell lines. 
3.2 Construction of Glucagon-Like Peptide-1 Plasmid by Using 
Optimal Transcriptional Regulatory Elements 
3.2.1 Experimental Materials and Methods 
3.2.1.1 Construction of GLP-1 Plasrnids Using Different Promoters 
Figure 3.2 shows the sequence of GLP-1 cDNA. A plasmid containing an 
expression cassette for GLP-1 (7-37) was constructed as follows. By using a 
DNA synthesizer, the GLP-1 (7-37) gene was synthesized. The start codon 
encodes methionine. If the N-terminal amino acid of the produced GLP-1 is also 
methionine, then GLP-1 will not be in an active form, because the first two amino 
acids of GLP-1 encompass its receptor binding domain. Therefore, a furin 
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Figure 3.2 Sequence of GLP-1 cDNA. Furin recognition site was underlined. 
recognition site (RGRR) was introduced into the GLP-1 cDNA to produce the 
active form of GLP-1 (Figure 3.3). When the produced GLP-1 is secreted from 
the cell, the methionine is cleaved by furin in the Golgi apparatus. 
105 
Three different promoters were tested also, including the CMV 
promoter/enhancer, the chicken beta-actin promoter/enhancer and the SV40 
promoter/enhancer. 
For the CMV promoter/enhancer and the chicken beta-actin 
promoter/enhancer, pCI vector (Promega, Madison, WI) was used, and for the 
SV40 promoter/enhancer, pSI vector (Promega, Madison, WI) was used. The 
plasmid p~GLP-1 has chicken ~-actin promoter and enhancer taken from 
pEBActNII. The construction process was as follows. 
Schematics of plasmid containing CMV promoter/enhancer, chicken ~­
actin promoter/enhancer, or SV40 promoter/enhancer and GLP-1 are shown in 
Figure 3.4, 3.5 and 3.6, respectively. 
The synthesized GLP-1 (7-37) cDNA was treated with Nhel and Xba/. In 
the case of the pCI-GLP1 plasmid, the protein coding sequence begins at 
position 1053 and terminates at position 1165. 
In the case of the pSI-GLP1 plasmid, the protein coding sequence begins 
at position 678 and terminates at position 790. To construct this plasmid the 
vector was cloned into a pSI vector at Nhel and Xbal sites. 
In the p~GLP1 plasmid the protein coding sequence begins at position 
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SV40 late polyadenylation signal 
Figure 3.4 Schematic of pCI-GLP1. The structure of the pCIGLP1 plasmid. The 
locations of the CMV promoter and the SV40 polyadenylation sequences are 










SV40 late polyA signal 
Phage f1 
region 
Figure 3.5 Schematic of pSI-GLP1. The structure of the pSIGLP1 plasmid. The 
locations of the Simian Virus 40 promoter and the SV40 polyadenylation 
sequences are shown. The furin cleavage site is between the start codon and the 
GLP-1 cDNA. 
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Kpnl (4Q16) SV40 polyadenylation site 






Figure 3.6 Schematic of pbeta-GLP1. The structure of the p~GLP1 plasmid. The 
locations of the chicken ~ actin promoter and the SV40 polyadenylation 
sequences are shown. The furin cleavage site is between the start codon and the 
GLP-1 cDNA. 
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3.2.1.2 Characterization of Plasmids 
Each plasmid was confirmed by restriction mapping and partial 
sequencing. The pCI-GLP1 and pSI-GLP1 plasmid was digested with Nhel and 
Xbal, and the pJ)-GLP1 was digested with Kpnl and Xbal. The fragments were 
separated using a 1 % agarose gel, and then their size was identified to confirm 
the construction. The sequencing was performed using T7 promoter primer, 
which is complementary to the sequence upstream of multicloning site of each 
plasmid (University of Utah Health Sciences DNA sequencing facility). 
3.2.1.3 Characterization of GLP-1 Plasmids with Carrier 
As a carrier, polyethyleneimine (PEl) was used. The carrierlDNA 
complexes were prepared by self assembly. PEl (branched, 25 kDa) was 
purchased from Polysciences Inc. (Warrington, PA). Stock PEl solution (1.25 
mg/ml) dissolved in ultra-pure water was used for all experimental procedures. 
The diluted carrier solution was slowly dripped into the prepared DNA plasmid 
solution and left for 30 minutes for formation of complex. To estimate the electric 
charge interaction between cationic PEl and anionic plasmid DNA, the calculated 
number of nitrogen atoms in PEl was divided by the phosphate atoms in DNA 
(NIP ratio). The PEIIDNA complex was prepared at a 5/1 NIP ratio for 
transfection. The formation of PEl/DNA complexes was routinely monitored by 
1.0% agarose gel electrophoresis. 
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3.2.1.4 In vitro Transfection 
Human hepatoma (HepG2) cell line was maintained in cell culture media 
supplemented with 10 % fetal bovine serum (FBS) and antibiotics (penicillin and 
streptomycin). The cultured cells were plated in 6 well plates at initial density of 5 
x 105 cells/well for 24 hours prior to transfection. All experiments were performed 
in triplicate. The transfection was carried out in serum-free media. After 24 hours, 
the cells were washed twice with serum-free medium, and then 2 ml of fresh 
serum-free medium was added. The polymer/plasmid complexes were added to 
the cells. The cells were then incubated for 4 hours at 37°C in 5 % CO2 and 
95 % air incubator. The amount of plasmids for transfection was 6 I-1g per each 
well. After 4 hours, the transfection mixtures were removed and 2 ml of fresh 
media with 10 % FBS was added. The cells were incubated for an additional 48 
hours, and samples were prepared for the GLP-1 assay. 
3.2.1.5 ELISA of GLP-1 
To evaluate the amount of GLP-1 released, the concentration of the GLP-
1 in the medium was determined by ELISA using GLP-1 (active) ELISA kit (Linco, 
St. Charles, MO). The expressed GLP-1 should be secreted in its active form for 
therapeutic purposes. To assess this, an ELISA assay for the active form of GLP-
1 was performed 48 hours after transfection. This assay has been developed to 
measure biologically active glucagon-like peptide-1 (7-36, 7-37) in plasma, serum 
or tissue culture medium. It is a noncompetitive immunoassay based on enzyme 
labeled quantification of GLP-1 detected by a fluorogenic substrate. Since the 
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amount of fluorescence generated is directly proportional to the concentration of 
active GLP-1 in the unknown sample, the latter can be derived by interpolation 
from a reference curve generated in the same assay with reference standards of 
known concentrations of active GLP-1. The plate was read by a fluorescence 
plate reader with an excitation I emission wavelength of 355nm 1460nm. 
3.2.1.6 Statistical Analysis of ELISA Data 
The amount of GLP-1 produced from different amounts of each plasmid 
was conlpared. Data from ELISA were analyzed by two-way AN OVA for 
repeated measures using a generalized linear model. In all cases a p value of 
<0.05 was considered to be statistically significant. 
3.2.2 Results 
3.2.2.1 Construction of GLP-1 Plasmid 
In this study, it was hypothesized that a GLP-1 gene delivery system 
could sustain the protein release in the body to overcome the major drawback of 
short half-life of GLP-1. However, creating a system that would produce the 
active form of GLP-1 requires an extra step. The first two amino acids of GLP-1 
(7-37) are important because it is a receptor binding domain. If the start codon, 
which encodes methionine, is placed just before GLP-1 cDNA in the plasmid, the 
active form of GLP-1 (7-37) cannot be produced because of a masked receptor 
binding domain. As mentioned in the introduction, a GLP-1 minigene containing 
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plasmid was tested for in vitro transfection of mouse insulinoma cells [1-2]. They 
used a natural posttranslational process to make active GLP-1 in pancreatic islet 
f)-cells. In this study, a furin cleavage site was placed between the start codon 
and GLP-1 cDNA to produce the active form of GLP-1. Furin is one of the 
endoproteases found in the Golgi apparatus in most mammalian cells. 
3.2.2.2 Production of GLP-1 in Transfected HepG2 Cells 
The expressed GLP-1 should be secreted in its active form for 
therapeutic purposes. To assess this, an ELISA assay for the active form of GLP-
1 was performed 48 hours after transfection. The active form of GLP-1 was 
detected in the cell culture media by ELISA assay, suggesting that the expressed 
GLP-1 was secreted into the cell culture media by GLP1 plasm ids. 6 J.lg of 
pSIGLP1 transfected HepG2 cells were assayed for GLP-1 production produced 
4 fold more GLP-1 than that from 6 J.lg pCIGLP1 transfected HepG2 cells (27.5 ± 
4.5 ng/L vs. 129.3 ± 16.2 ng/L) (Figure 3.7). 
3.2.3 Discussion 
Generally the level of expression of a foreign gene from a recombinant 
plasmid is influenced by the number of genes in the cell, the rate of transcription 
of the gene, and the stability of the mRNA transcription. It has been known that 
the gene expression level is mainly regulated by the level of transcription. 
Therefore, the optimization of transcriptional regulatory elements is required to 















pCIGLP1 pSGLP1 pSIGLP1 
Figure 3.7 In vitro transfection assay in HepG2 cells for GLP-1 expression. The 
GLP-1 levels after transfection of the PEI/GLP1 plasmid complex into HepG2 
cells (6 x 105 cells per well), the media was collected and the active GLP-1 level 
was measured by ELISA. The graph represents the average ± SE of six 
experiments. *P<0.05 as compared to pCIGLP1! **P<0.05 as compared to 
p~GLP1. 
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include the enhancer and promoter. Enhancers are cis-acting DNA segments 
stinlulating transcription from promoters [26]. The presence of an active 
enhancer results in an increased density of RNA polymerase II molecules at the 
linked gene leading to a higher transcription rate [27]. 
In this study, to compare relative promoter/enhancer strengths, three 
plasm ids containing different promoters/enhancers were constructed and tested 
in vitro. The strength of each promoter/enhancer has been tested indirectly by 
monitoring the GLP-1 gene activity following direct introduction into the cell via 
transfection of the plasmid/carrier complex into the cells. The comparison of 
different promoters/enhancers showed that the SV40 promoter/enhancer yielded 
the highest expression in cultured HepG2 cells. 
The SV40 enhancer is represented by a DNA sequence of 72 bp with 
multiple motifs connected with transcriptional activation [28]. Some proteins 
recognizing these motifs have been identified as transcriptional activators [29]. In 
other words, these sequences have affinity for nuclear transcription factors. 
3.3 Modification of Glucagon-Like Peptide-1 Plasmid with Nuclear 
Factor Kappa-B Binding Sites 
3.3.1 Experimental Materials and Methods 
3.3.1.1 Construction of Plasmid with Nuclear Factor Kappa-B 
Binding Sites 
To modify previously constructed plasmids, NFKB binding sites were 
inserted after the SV40 polyadenylation site of each plasmid (Figure 3.8). A 
Start 
Codon 
Furin recognition site 
(RGRR) 
GLP·1 (7-37) 





Phage f1 region 
Figure 3.8 Illustration of GLP-1 plasmid modification with NFKB binding sites 
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fragment consisting of five direct repeats of the IKB motif, 5' -GGGGACTTCC-3' 
was synthesized using a DNA synthesizer. 
Each plasrrlid was confirmed by restriction mapping and partial 
sequencing. The pCI-GLP1-NFKB and pSI-GLP1-NFKB plasmid was digested 
with Bglll and Xbal, and the p~-GLP1-NFKB was digested with Kpnl and Xbal. 
The fragments were separated using a 1 % agarose gel, and then their size was 
identified to confirm the construction. The sequencing was performed using T7 
promoter primer, which is compliment to the sequence upstream of multicloning 
site of each plasmid. 
3.3.1.2 In vitro Transfection 
Human hepatoma (HepG2) cells were maintained in the cell culture 
media with 10 % FBS and antibiotics (penicillin and streptomycin). Cells were 
grown in same environment. Transfection process and sample preparation was 
same as the previous in vitro transfection. 
After washing transfected cells with PBS, the total RNA was prepared by 
aCid-guanidium thiocyanate-phenol- chloroform extraction, using RNAwiz 
(Ambion, Austin, TX). Any residual DNA was removed from RNA by incubating 
the RNA extract with DNase (Promega, Madion, WI) at 37°C for 30 minutes. The 
concentration of RNA was measured by the absorbance at 260 nm and 280 nm. 
Two microgram of the total RNA was hybridized to the backward primer and 
reverse transcribed using AMV reverse transcriptase (Promega, Madion, WI). 
The reverse transcribed sarrlples will be amplified by polymerase chain reaction 
(PCR), using Taq polymerase (Promega, Madison, WI). The sequences of the 
specific oligonucleotide primers are as follows: GLP-1 forward primer, 5'-
CAGAAGTTGGTCGTGAGGCA-3'; GLP-1 backward primer, 5'-
GCCTTTCACCAGCCAAGCAA-3'. The PCR reaction consists of 94°C for 5 
minutes, 25 cycles at 94°C for 30 seconds, 55°C for 30 seconds, 72°C for 1 
minute, followed by an extension of 10 minutes at 72°C. The size of the 
expected product is 112 bp for GLP-1. 
3.3.1.5 In vitro Biological Activity Assay of GLP-1 
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To determine if insulin secretory action of GLP-1 is glucose dependent, 
islet cells were cultured with the GLP-1 transfected cells under various glucose 
concentrations. 
3.3.1.5.1 Isolation of Rat Islets 
Islets of Langerhans were isolated from male SD rat pancreas by a 
collagenase digestion technique. Each rat was fasted for approximately 12 hours 
prior to the islet isolation procedure with water available ad libitum. After 
anesthetizing rats, 5-10 ml of blood was removed by a cardiac puncture to avoid 
blood contamination during the dissection procedure. The pancreas was exposed 
by using a midline incision. A collagenase solution in Hank's Balanced Salt 
Solution (HBSS) 4-8 ml was injected into the pancreas via the common bile duct. 
The pancreas was dissected and incubated at 37°C for 5-10 minutes 
with gentle vortexing every 2 minutes. The digested tissue was rinsed twice with 
cold HBSS at 4 °C in order to stop the tissue digestion process. The pancreatic 
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tissue was passed through a 500-J.lm mesh. The islets were purified by using a 
Ficoll density gradient. The islets were rinsed twice with HBSS to remove the 
toxic Ficol! solution. The islets were cultured in a medium of RPMI-1640 
complete 100G medium. RPMI-1640 complete 100G medium contains RPMI-
1640 supplemented with 100-mg/dl glucose, antibiotics (penicillin, streptomycin, 
amphotericin B), and 10% FBS. The islets were incubated in the medium for one 
day at 37°C in a 95% air 50/0 C02 incubator. The islets were handpicked under 
using a light microscope at 50X magnification. The handpicked islets were again 
incubated under the same conditions for 24 to 48 hours prior to their use in co-
culture experiment. 
3.3.1.5.2 Co-culture of Isolated Rat Islets with the Transfected Cells 
The cells were cultured and transfected with each plasmid by using the 
same procedure as described previously. The 30 islets were carefully transferred 
into the transfected cell culture system by using cell culture insert for a physical 
separation. Then, the culture medium was changed to fresh RPMI-1640 medium 
with different glucose content (50 mg/dl and 300 mg/dl). After 4 hours of co-
incubation, the culture medium was collected for GLP-1 and insulin assay. This 
experiment was repeated until the result can account for statistical significance 
(Statistical analysis is in the next section). 
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3.3.1.5.3 RIA of Insulin 
The radioimmuno assay is based upon the competition of 125-I-peptide 
and peptide (either standard or unknown) binding to the limited quantity of 
antibodies specific for the peptide in each reaction mixture. As the quantity of 
standard or unknown in the reaction increases, the amount of 125-I-peptide able 
to bind to the antibody is decreased. By measuring the amount of 125-I-peptide 
bound as a function of the concentration of peptide in standard reaction mixtures, 
it is possible to construct a standard curve from which the concentration of 
peptide in unknown samples can be determined. Thus, four basic components 
are necessary for a radioimmunoassay system which include following. (1) a 
specific antiserum to the antigen to be measured (2) a radioactive labeled form of 
the antigen (3) a method whereby antibody-bound tracer can be separated from 
the unbound tracer (4) an instrument to count radioactivity, which is the gamma 
counter in the CCCD laboratory, University of Utah. In this study, the plasma 
insulin level was determined by using Insulin RIA kit (ICN Pharmaceuticals, 
Costa Mesa, CA). 
3.3.1.5.4 Statistical Analysis 
The amount of insulin produced from different glucose concentration was 
compared. Two-way ANOVA for repeated measures (Generalized Linear Model) 
was used to analyze data from Insulin RIA. In all cases a p value of <0.05 was 
considered to be statistically significant. 
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3.3.2 Results 
3.3.2.1 Production of GLP-1 in Transfected HepG2 Cells 
The expressed GLP-1 should be secreted in its active form for 
therapeutic purposes. To assess this, an ELISA assay for the active form of GLP-
1 was performed 48 hours after transfection. Figure 3.9 shows the amount of 
GLP-1 in each medium after transfection with each plasmid. Two micrograms of 
plasmid DNA complexed with PEl at the NIP ratio 5: 1 were used to transfect the 
cells in 6-well culture plates. Forty eight hours after transfection, the 
concentrations of GLP-1 in culture media measured by ELISA showed 
approximately a 5 fold higher level in the pSIGLP1 NFKB transfected cells than in 
the pCIGLP1 transfected cells. 
3.3.2.2. Expression of GLP-1 mRNA in Transfected HepG2 Cells 
The pSIGLP1/PEI and pSIGLP1 NFKB/PEI complex was transfected into 
HepG2 cells to evaluate its expression of GLP-1. The sequences of the specific 
oligonucleotide primers were as follows: GLP-1 forward primer, 5'-
CAGAAGTIGGTCGTGAGGCA-3'; GLP-1 backward primer, 5'-
GCCTTTCACCAGCCAAGCAA-3'. As a result, the GLP-1 mRNA was detected in 
the pSIGLP1 and pSIGLP1 NFKB plasmid transfected cells (Figure 3.10). 
This result suggests that the detected mRNA was expressed by the 
exogenous transferred pSIGLP1 and pSIGLP1 NFKB plasmid, not by the 
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Figure 3.9 In vitro transfection assay in HepG2 cells for GLP-1 expression. The 
GLP-1 levels after transfection of the PEIIGLP1 plasmid complex into HepG2 
cells (6 x 105 cells per well), the media was collected and the active GLP-1 level 
was measured by ELISA. The graph represents the average ± SE of six 
experiments. *P<0.05 as compared to pCIGLP1, **P<0.05 as compared to GLP-
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Figure 3.10 Reverse transcriptase-polymerase chain reaction (RT -peR). M, 
molecular marker; Lane 1, polymer only; Lane 2, empty plasmid; Lane 3, 
PEl/pSIGLP1; Lane 4, PEI/pSIGLP1 NFKB. 
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3.3.2.3 In Vitro Biological Activity Assay of GLP-1 
It was studied whether the secreted GLP-1 from the transfected HepG2 
cells can stimulate secretion of insulin from isolated rat islets. The isolated rat 
islets were cultured with the pSIGLP-1 and pSIGLP1 NFKB transfected HepG2 
cells. There was no enhancement of insulin secretion under low glucose 
concentration (50 mg/dL). However, a remarkable increment of insulin secretion 
occurred under high glucose concentration (300 mg/dL) (Figure 3.11). The 
transfected HepG2 cells in each well produced 13.2 jJg/L GLP-1 and 16.3 jJg/L 
GLP-1 over 4 hours, respectively. These results showed that GLP-1 significantly 
stimulated the secretion of insulin under high glucose conditions but not under 
low glucose conditions. 
3.3.3 Discussion 
Non-viral delivery of GLP-1 plasmid was proposed for treatment of 
diabetes. The goal of this study was to increase GLP-1 expression level by 
modifying GLP-1 plasmid with NFKB binding sites. 
There have been several attempts to improve nuclear transport of plasmid 
DNA, such as electrostatic binding of DNA to NLS-containing proteins [30, 31] or 
peptides [32] or lipids [33], as well as sequence-specific binding of DNA to 
karyophilic proteins [34]. However, the stability of those conlplexes has been 
unpredictable. NLS sequences are positively charged and interact strongly with 
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Figure 3.11 Insulin production in co-culture isolated rat islets with pSIGLP1 
transfected HepG2 cells. Two days after gene transfection, the co-culture (30 
isolated rat islets with 6 x 105 HepG2 cells) was performed under two different 
conditions; 2.7 and 16.5 mmol/L of glucose concentration in n1edia. The graph 
represents the average ± SE of six experiments. *P<0.05 as compared 
to control under high glucose condition, **P<0.05 as compared 
to pSIGLP1 under high glucose condition. 
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DNA sequence elements. Binding affinity of NFKB to its DNA binding sites is high, 
and complex formation between NFKB and the plasmid DNA may protect the 
DNA from entering into endocytic pathway. 
The ability of NFKB to n1ediate delivery of biologically active GLP-1 
plasmid DNA has been tested indirectly by monitoring the GLP-1 gene activity 
following direct introduction into the cell via transfection of the plasmid with NFKB 
binding sites into the cells. 
The plasmid of pSIGLP1 NFKB showed higher gene activity than pSIGLP1 
with an increase of 1.5-fold. The enhancement by using NFKB binding sites was 
relatively smaller than cases with pCIGLP1 and p~GLP1. This result could be 
explained by the fact that the SV40 enhancer can mediate nuclear transfer of the 
DNA by binding to ubiquitously expressed transcription factors. 
By RT-PCR, it was shown that the detected mRNA was expressed by the 
exogenously transferred pSIGLP1 and pSIGLP1 NFKB plasmid, not by the 
endogenous GLP-1 gene. 
Co-culture assay of the GLP-1 plasmid transfected cells with isolated rat 
islet cells demonstrated that GLP-1 increased insul in secretion from transfected 
HepG2 cells, compared to controls during a hyperglycemic challenge. Produced 
GLP-1 has an insulinotropic effect under high glucose concentrations (300 
mg/dL) but not under low glucose concentrations (50 mg/dL). These results are 
clinically desirable and support the safety of the GLP-1 treatment because there 
is no risk of hypoglycemia. 
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3.4 Conclusions 
To achieve therapeutic activity of GLP-1, the expression level should be 
high enough to produce sufficient level of GLP-1 for lowering high glucose level 
of diabetic subjects. The aim of this study was to design a new and effective 
GLP-1 delivery system for therapeutic use for type 2 diabetes treatment based 
upon construction of efficient GLP-1 plasmid. For effective gene delivery, 
expression efficiency should be enhanced. The expression levels of the 
introduced gene depend mainly on the strength of transcriptional regulatory 
elements and the transduction efficiency of the gene transfer vector. In this study, 
the main focus was on the strength of promoter/enhancer and enhancement of 
nuclear import. 
First, three plasrnids containing different promoters/enhancers were 
constructed and tested in vitro to compare relative promoter/enhancer strengths. 
The strength of each promoter/enhancer was tested indirectly by monitoring the 
GLP-1 gene activity following direct introduction into the cell via transfection of 
the plasmid/carrier complex into the cells. The comparison of different 
promoters/enhancers showed that the SV40 promoter/enhancer yielded the 
highest expression in cultured HepG2 cells. 
Then, GLP-1 plasmid was modified with NFKB binding sites. The ability of 
NFKB to enhance transport of GLP-1 plasmid DNA has been tested by 
monitoring the GLP-1 gene activity following transfection of the plasmid into the 
cells. After transfection, the concentrations of GLP-1 showed approximately a 5 
fold higher level in the pSIGLP1 NFKB transfected cells than in the pCIGLP1 
transfected cells. 
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As shown by the data, more active GLP-1 was expressed after 
transfection of newly designed GLP-1 plasrnid with SV40 promoter/enhancer 
than plasmid with CMV promoter/enhancer or ~-actin promoter/enhancer. Also, 
modification of GLP-1 plasmid with NFKB binding sites results in increase of 
expression level. Biological activity of produced GLP-1 after transfection was 
tested and it was shown that GLP-1 has an insulinotropic effect under high 
glucose concentration but not under low glucose concentration. These results 
suggest the safety of the GLP-1 treatment without any risk of hypoglycemia. 
Therefore, the selected plasmid will be tested with type 2 diabetic animal model 
to study the feasibility of GLP-1 gene delivery as treatment of type 2 diabetes. 
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CHAPTER 4 
GLUCAGON-LIKE PEPTIDE-1 GENE DELIVERY IN TYPE 2 
DIABETIC ANIMAL MODEL 
4.1 Introduction 
Glucagon like peptide-1 (GLP-1) is a potent insulinotrophic hormone, 
which makes GLP-1 an attractive candidate for the treatment of type 2 diabetes. 
However, the short plasma half-life of the active forms of GLP-1 poses an 
obstacle to the sustained delivery of this peptide. In this study, the effect of GLP-
1 gene delivery in vivo using a new plasmid constructed with a GLP-1 (7-37) 
cDNA was studied. This cDNA contains a furin cleavage site between the start 
codon and the GLP-1 coding region. The expression of the GLP-1 gene in this 
study is driven by a SV-40 promoter. For type 2 diabetic animal model, diet 
induced obese (010) mice were used. 
Type 2 diabetes is characterized by excessive hepatic glucose production, 
decreased insulin secretion, and insulin resistance [1]. Elevated glucose level 
causes increased oxidative stress due to increased production of reactive oxygen 
species (ROS) [2]. The oxidative stress leads to the activation of stress-sensitive 
signaling pathways and worsens insulin secretion and action. NFKB is a major 
intracellular target of hyperglycemia and oxidative stress. Activators of NFKB 
include elevated glucose, ROS, tumor necrosis factor-a (TNF-a), and other 
proinflarrlmatory cytokines [3]. 
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One of the molecules that accumulates in diabetic patients is TNF-a. It 
has been shown that more amount of TNF-a produced in type 2 diabetic patients. 
A dramatic increase in the TNF-a release has been reported to be mediated by 
ROS via activation of transcription factor NFKB in cultured cells incubated with 
high glucose for 18 hours [4]. The production of TNF-a depresses the synthesis 
of glut 4, and the loss of glut 4 inhibits an insulin stimulated cell from glucose 
uptake. TNF-a is the major cytokine, which stimulates NFKB effectively. 
Therefore, new GLP-1 plasmid was designed by incorporating NFKB binding 
sites to GLP-1 plasmid for the treatment of diabetes. Figure 4.1 shows the 
schematic of NFKB activation and its subsequent nuclear entry. In diabetic 
subjects, high glucose level and TNF-a phosphorylate IKB. Thus, NFKB is 
activated by phosphorylation and degradation of IKB. 
4.2 Experimental Animals 
Male C57BU6J mice, 4 weeks of age, were used to study the effect of 
GLP-1 plasmid on type 2 diabetic subjects. Mice were purchased from Jackson 
Laboratory (Bar Harbor, ME). To make a fully developed insulin resistant diet 
induced obese (010) animal phenotype, 50 animals were fed with a high fat and 
high calorie diet (60 kcal% fat, 012492, Research Diet, New Brunswick, NJ) for 3 
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Figure 4.1 Model of NFKB activation in diabetes mellitus. 
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syndrome characterized by obesity, high blood glucose and low plasma insulin 
level. Blood samples were obtained from the tail vein for glucose, GLP-1 and 
insulin assays. Animals were maintained under virus and antibody free conditions 
in climatized rooms with free access to sterilized tapwater and special food for 
010 mice. 
4.3 Experimental Materials and Methods 
4.3.1 Injection of GLP-1 Plasmid with PEl 
All animals were kept under specific pathogen free conditions in the 
animal facility. Anesthesia was induced by intramuscular injections of 
pentobarbital (6 mg/kg). The experimental animals, Male 010 mice, 4 months old, 
were divided into five groups. Each group consisted of fifteen mice for three sets 
of assay. In addition to blood sampling, IPGTT was done 2 days after injection. 
The first group was not injected. The second group was injected with the carrier 
PEl only. The third group was injected with the PEl/empty plasmid complex, with 
the NIP ratio of 5/1. The next two groups were injected with the PElipSIGLP1 
and PEI/pSIGLP1 NfKB plasmid complex. Blood samples were withdrawn at day 
0,2,4, 7, 10, 14, 17 and 21 after injection to measure blood glucose, GLP-1, and 
insulin concentrations. 
4.3.2 Assessment of Glucose Level 
Blood glucose level was tested using glucometer (Accu-check Advantage 
from Roche Oiagonistics Corporation, Indianapolis, IN). 10 J,JI of blood is required 
for each measuring. 
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4.3.3 Assessment of GLP-1 Level 
To evaluate the efficacy of GLP-1 gene delivery, the concentration of the 
GLP-1 in the plasma was determined by ELISA using GLP-1 (active) ELISA kit 
(Linco, S1. Charles, MO). 
4.3.4 Assessment of Insulin Level 
To evaluate the efficacy of GLP-1 gene delivery, the concentration of 
insulin in the plasma was determined by RIA using Insulin RIA kit (ICN 
Pharmaceuticals, Costa Mesa, CA). 
4.3.5 Statistical Analysis 
Data for the effect of GLP-1 gene therapy in type 2 diabetic animal model 
was analyzed by 2-way ANOVA for repeated measures using a generalized 
linear model. In all cases a p value of <0.05 was considered to be statistically 
significant. 
4.3.6 Intraperitoneal Glucose Tolerance Test 
A glucose tolerance test was used to evaluate the ability of the animals to 
tolerate a standard glucose load. Mice (n=5 each at 2 days after injection) were 
fasted overnight before the intraperitoneal glucose tolerance test. A pre-load 
blood sample will be taken and a glucose load of 1 g/kg was administered via 
intraperitoneal injection. Subsequent blood samples were taken 0, 15, 30, 60, 
and 120 minutes after injection. Blood samples were obtained from the tail vein 
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and used for measuring the levels of insulin. This procedure allowed for 
collection without catheterization of blood vessel. All animals were anesthetized 
by intramuscular injections of pentobarbital (6 mg/kg) before the glucose injection. 
4.4 Results and Discussion 
The pSIGLP1/PEI and pSIGLP1 NFKB/PEI (NIP ratio 5:1) complex (200 
1-11) was injected into the mice via tail veins. All mice tolerated the injections well, 
and no injection-related deaths occurred. It was studied whether the delivered 
pSIGLP1 NFKB plasmid can decrease blood glucose levels in 010 mice, and the 
effect of incorporating N FKB binding sites into plasmid. After intravenous 
administration of 200 I-Ig of the PEllpSIGLP1 NFKB complex, the blood glucose 
levels began to decrease after the injection (Figure 4.2). This decrease continued 
until the second day following administration, after which the blood glucose levels 
increased until the 21 th day after injection. However, the blood glucose levels did 
not return to the preadministration base line until the 1 ih day after injection. The 
control groups showed no significant change in their blood glucose levels during 
a similar time period. The second group of animals that received pSIGLP1/PEI 
showed a similar pattern of glucose level change as the pSIGLP1 NFKB/PEI 
group, but the change of blood glucose in the pSIGLP1 group was relatively 
smaller than pSIGLP1 NFKB group. 
The plasma level of GLP-1 from each group was also monitored. In 
conjunction with the changes in blood glucose levels, the PEI/pSIGLP1 NFKB 
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Figure 4.2 Blood glucose level changes after injection of PEI/GLP-1 plasmid. The 
DIO mice received intravenous injection of PEl (square) or PEl/empty plasmid 
(triangle) or PEI/pSIGLP1 (x), or PEI/pSIGLP1 NFKB (circle). Each group was 
composed of six mice, and the graph represents the average ± SE. *P<O.05 as 
compared to control. 
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injection (Figure 4.3). The GLP-1 level steadily decreased through the 28th day of 
the study. The control groups showed almost no changes in GLP-1 concentration. 
The plasma insulin level was assayed to see the insulinotropic effect of 
GLP-1. The pattern of the insulin concentration change in the PEI/pSIGLP1 NFKB 
group mirrored the temporal profile of the plasma GLP-1 levels. This group's 
plasma insulin concentration value increased 2.5 fold above the baseline (Figure 
4.4). The control groups showed minimal changes in plasma insulin 
concentration. 
Two days after the complex was injected, plasma GLP-1 values 
increased dramatically, and these values gradually returned to baseline levels 
after 3 weeks (Figure 4.3). Blood glucose levels also decreased, and returned to 
preinjection levels after 3 weeks (Figure 4.2). Plasma insulin level also increased, 
and gradually returned to baseline 17 days after injection (Figure 4.3). An 
intraperitoneal glucose tolerance test (IPGTT) was performed to verify the 
improvement of glucose tolerance. The blood glucose level showed marked 
decrease (Figure 4.5). 
The amount of food consumption and the change in body weight after 
injection was also monitored. Food consumption decreased 2 days after injection, 
and gradually returned to preinjection values after 14 days (Figure 4.6). Body 
weight also decreased after injection (Figure 4.7). The time sequences of the 
changes of parameters showed close correlation with the changes of the plasma 
GLP-1 levels. After continuous subcutaneous infusion of GLP-1, patients with 
141 
* * 70 * 
* 60 









'-~~~--~--I I----+- pSIGLP1 NfkB 
i ... x-. - pSIGLP1 . 
I I 
I---,:r~ empty plasmid j 
! - --- - polymer only I 1--. ~ No. injection J 
o 3 6 9 12 15 18 21 
Time (days) 
Figure 4.3 Plasma GLP-1 level changes after injection of PEI/GLP-1 plasmid. 
The 010 mice received intravenous injection of PEl (square) or PEl/empty 
plasmid (triangle) or PEI/pSIGLP1 (x), or PEI/pSIGLP1 NFKB (circle). Each group 
was composed of six mice, and the graph represents the average ± SE. *P<O.05 
as compared to control. 
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Figure 4.4 Plasma insulin level changes after injection of PEIIGLP-1 plasmid. 
The 010 mice received intravenous injection of PEl (square) or PEl/empty 
plasmid (triangle) or PEI/pSIGLP1 (x), or PEI/pSIGLP1 NFKB (circle). Each group 
was composed of six mice, and the graph represents the average ± SE. *P<O.05 
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Figure 4.5 Blood glucose level in 010 mice after glucose challenge (IPGTT). At 
day 2, blood glucose levels in mice treated with nothing (open circle) and 
PEI/pSIGLP1 NFKB (closed circle) were assayed for the indicated times after 
intraperitoneal glucose injection. The graph represents the average ± SEt each 
group was composed of six mice. Statistical significance between groups (control 
vs. PEI/pSIGLP1 NFKB) was determined by repeated-measures ANOVA: *P<0.05 
as compared to control. 
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Figure 4.6 Change in food consumption was monitored. Each group was 
composed of six mice, and the graph represents the average ± SE. *P<O.05 as 

























Figure 4.7 Change in body weight was monitored. Each group was composed of 
six mice, and the graph represents the average ± SE. *P<O.05 as compared to 
control. 
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type 2 diabetes reported a reduction in appetite, which led to significant 
reductions in body weight [5]. Several reasons seem to be involved with 
reductions in body weight. First, GLP-1 decreases gastric emptying rates. 
However, the reduced sensation of appetite was reported not only in the 
postprandial state, but also in the fasting state and before meal ingestion in 
humans [6]. This suggests mechanisms other than decreased gastric emptying 
also contribute to body weight reduction. It has been shown that the central 
administration of GLP-1 inhibits food intake in rodents [7]. Since circulating GLP-
1 can access GLP-1 receptors in brain, it will participate in the regulation of 
appetite [8]. It is also possible that gastric distension activates GLP-1 containing 
neurons, so it can act as an inhibitor of food intake [9]. 
4.5 Conclusions 
GLP-1 is very promising candidate for type 2 diabetes treatment. GLP-1 
has many advantages for treating type 2 diabetes. However, there is a major 
limitation to clinical applications due to the extremely short half-life of GLP-1 in 
vivo. It has been suggested that continuous infusion of GLP-1 can normalize 
hyperglycemia in type 2 diabetes [10]. In this study, GLP-1 plasmids with NFKB 
binding sites was delivered and showed GLP-1 expression in vivo for an 
extended time. A single injection of GLP-1 plasmid/PEl complex into 010 mice 
resulted in increasing insulin secretion and decreasing blood glucose level that 
was maintained for more than 2 weeks. Body weight was also decreased after 
injection of GLP-1 plasmid/PEl complex. Since there is no risk of hypoglycemia 
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under higher concentrations of GLP-1, a potent promoter/enhancer, SV40 
promoter/enhancer, was used for GLP-1 plasmid. GLP-1 is produced in intestinal 
L-cells in the body. GLP-1 plasmid was delivered systemically by intravenous 
injection. A furin cleavage site was inserted in the GLP-1 coding region in order 
to separate methionine which the start codon encodes. Thus, active form of GLP-
1 could be produced after delivery of plasmid/polymer complex. 
In conclusion, GLP-1 plasmid was designed for high expression level and 
as a result of its delivery blood glucose level was significantly lowered in a type 2 
diabetic animal model. Also, delivered GLP-1 gene showed insulinotropic activity. 
Therefore, it is proposed that design of GLP-1 plasmid and its delivery can be 
effectively used for treatment of type 2 diabetes. 
148 
4.6 References 
1. DeFronzo, R. A. (1997) Pathogenesis of type 2 diabetes: metabolic and 
molecular implications for identifying diabetes genes. Diabetes Rev. 5, 177-269. 
2. Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic 
complications. Nature 414,813-820. 
3. Barnes, P. J., and Karin, M. (1997) Nuclear factor- KB-a pivotal transcription 
factor in chronic inflammatory diseases. N. Eng. J. Med. 336, 1066-1071. 
4. Guha. M., Bai, W., and Nadler, J. L. (2000) Molecular Mechanisms of Tumor 
Necrosis Factor alpha Gene Expression in Monocytic Cells via Hyperglycemia-
induced Oxidant Stress-dependent and -independent Pathways. J. BioI. Chern. 
275,17728-17739. 
5. Zander, M., Madsbad, S., Madsen, J. L., and Holst, J. J. (2002) Effect of 6-
week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, 
and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359, 824-
830. 
6. Gutzwiller, J. P., Goke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, 
D., Winterhalder, R., Conen, D., and Beglinger, C. (1999) Glucagon-like peptide-
1: a potent regulator of food intake in humans. Gut 44, 81-86. 
7. Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M., Meeran, K., 
Choi, S. J., Taylor, G. M., Health, M. M., Lambert, P. D., Wilding, J. P., Smith, D. 
M., Ghatei, M. A., Herbert, J., and Bloom, S. R. (1996) A role for glucagons-like 
peptide-1 in the central regulation of feeding. Nature 379, 69-72. 
8. Orskov, C., Poulsen, S. S., Moller, M., and Holst, J. J. (1996) Glucagon-like 
peptide I receptors in the subfornical organ and the area postrema are accessible 
to circulating glucagons-like peptide I. Diabetes 45,832-835. 
9. Vrang, N., Phifer, C. B., Corkern, M. M., and Berthoud, H. R. (2003) Gastric 
distension induces c-Fos in medullary GLP-1/2-containing neurons. Am. J. 
Physiol. 285, R4 70-R4 78. 
10. Toft-Nielsen, M. B., Madsbad, S., and Holst, J. J. (1999) Continuous 
subcutaneous infusion of glucagons-like peptide 1 lowers plasma glucose and 
reduces appetite in type 2 diabetic patients. Diabetes Care 22, 1137-1143. 
149 
CHAPTER 5 
SUMMARY AND FURTHER RESEARCH 
5.1 Summary of Conclusions 
In spite of its many remarkable advantages as a therapeutic agent for 
diabetes, GLP-1 is not immediately clinically applicable because of its extremely 
short half-life. The purpose of this research was to design the effective way of 
GLP-1 delivery for therapeutic use of GLP-1. GLP-1 is an insulinotropic hormone 
which increases insulin secretion in a glucose-dependent manner. Insulin 
secretion is only increased when concentrations of glucose is high and not at low 
to normal concentrations of glucose, therefore avoiding hypoglycemic episodes. 
The first half of the research studied the effects of GLP-1 delivery using a 
thermosensitive biodegradable triblock copolymer. The second half of this 
research was to design a new and effective GLP-1 delivery system for 
therapeutic use for type 2 diabetes treatment based upon construction of GLP-1 
plasmid and its delivery. 
To begin the study of the effect of GLP-1 delivery system using 
biodegradable injectable polymer, in vitro release experiment was performed to 
investigate the feasibility of GLP-1 polymeric drug delivery and to determine the 
duration of the system. The results from the experiment did show steady amount 
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of GLP-1 released from PLGA-PEG-PLGA triblock copolymer formulation depot 
more than ten days after single subcutaneous injection. 
The animal experiment with the type 2 diabetic model performed for this 
research project also investigated the effects of polymeric delivery of GLP-1. It 
was evident that the GLP-1 released from the thermosensitive biodegradable 
hydrogel (PLGA-PEG-PLGA triblock copolymer) formulation is bioactive as it 
stimulates insulin secretion in vivo. Also, GLP-1 released from PLGA-PEG-PLGA 
triblock copolymer formulation depot results in the improved glucose tolerance. 
Therefore, it was concluded that it is feasible to use PLGA-PEG-PLGA triblock 
copolymer formulation with zinc-complexed GLP-1 as a 2 weeks delivery system, 
making it a twice-a-month injection depot. 
For less frequent and more convenient administration of GLP-1, the GLP-
1 gene delivery systenl was attempted in this study. GLP-1 plasmid delivery 
allowed sustained secretion of active GLP-1 for an extended time. Thus a major 
limitation of current GLP-1 therapy can be overcome. As GLP-1 stimulates the 
cells, more insulin production occurs in pancreatic (3 cells. Since no reactive 
hypoglycemia occurs even with higher concentrations of GLP-1, a potent 
promoter was used in this system. Normally, the GLP-1 is produced in intestinal 
L-cells, and matures through the posttranslational process. In the case of non-
viral gene delivery, substantial amount of delivered DNA is taken up by 
hepatocytes. Thus, a furin cleavage site was placed in the GLP-1 coding region 
to release methionine that the start codon encodes. Therefore, the delivered 
GLP-1 plasmid/PEl conlplex could produce active GLP-1. 
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In conclusion, it has been established that GLP-1 gene delivery 
significantly decreased blood glucose concentration in a type 2 diabetic animal 
model. The results revealed that delivered GLP-1 gene stimulated insulin 
secretion, indicating that GLP-1 gene delivery represents a promising candidate 
for treatment of type 2 diabetes. 
5.2 Further Research 
GLP-1 is one of the most promising therapeutic agents for type 2 diabetes. 
It has been shown that GLP-1 administration can lead to a near-normalization of 
blood glucose levels in type 2 diabetic patients, even in patients with secondary 
failure of sulfonylurea and long-standing disease, admitted to hospital for insulin 
treatment [1, 2]. 
However, it has been shown that GLP-1 cannot be practically applied 
because of its extremely short half-life. Since the extremely short half-life is due 
to DPP-IV activity, DPP-IV resistant analogs have been developed as 
alternatives. The enzymatic cleavage occurs at the alanine in position two, thus 
analogs modified at this position were more resistant than GLP-1 itself. Such 
analogs retain a prolonged insulinotropic activity compared with native GLP-1. 
Therefore, GLP-1 dose can be reduced and its duration can be prolonged by 
using GLP-1 analog instead of native GLP-1. The effect of this GLP-1 analog 
should be carefully studied for clinical applications, because the GLP-1 analog 
will likely result in formation of antibodies in the body. 
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The results of many clinical studies demonstrate that GLP-1 may result in 
marked metabolic improvements, improvements in pancreatic functions, insulin 
sensitivity, and body weight. However, one study has clearly shown that the most 
important requirement for any therapeutic agent for type 2 diabetes is the ability 
to prevent progressive J3-cell deterioration [3]. It has been suggested that GLP-1 
has tropic effects for J3-cells, and also an ability to protect and preserve J3-cells in 
rodent model [4, 5, 6]. At present, no data are available with respect to tropic 
effects of GLP-1 on human J3-cells. Since the turnover of J3-cells in humans is 
much slower than that of rodents [7L tropic effects in humans may appear only 
after prolonged treatment with GLP-1. Therefore, further studies regarding tropic 
effects on human J3-cell would be required for clinical use of GLP-1 for type 2 
diabetes. 
In addition, the effect of combination therapy of GLP-1 with other 
treatments will be beneficial. It has been shown that combination therapy of GLP-
1 with metformin has additive effects [8]. 
For GLP-1 gene delivery, PEl was used as a nonviral carrier. Since viral 
carriers are expensive to produce, difficult to quality control, potentially damaging 
to the cells they infect, and most importantly they may cause potent immune 
responses that limit their use, it is desirable to develop nonviral systems. Nonviral 
gene delivery vectors offer numerous advantages such as excellent safety 
profiles, ability of carrying large amounts of DNA, and easy quality control. 
However, the current non-viral gene delivery systems including PEl have shown 
low transfection efficiency. Therefore, further development of the non-viral carrier 
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which has low cytotoxicity could improve the gene delivery efficiency and allow 
for the system to be delivered repeatedly when it is required. 
There are many obstacles still to overcome in the clinical use of GLP-1 
delivery system, and researchers are working to overcome each obstacle. With 
the combined efforts from each of fields, a successful and convenient GLP-1 
treatment will be possible in near future. 
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